Photo of Professor Christian Ottensmeier

Professor Christian Ottensmeier

Professor of Immuno-Oncology Molecular & Clinical Cancer Medicine

    Publications

    2021

    Automated Analysis of Proliferating Cells Spatial Organisation Predicts Prognosis in Lung Neuroendocrine Neoplasms (Journal article)

    Bulloni, M., Sandrini, G., Stacchiotti, I., Barberis, M., Calabrese, F., Carvalho, L., . . . Pattini, L. (n.d.). Automated Analysis of Proliferating Cells Spatial Organisation Predicts Prognosis in Lung Neuroendocrine Neoplasms. Cancers, 13(19), 4875. doi:10.3390/cancers13194875

    DOI: 10.3390/cancers13194875

    Using DNA sequencing data to quantify T cell fraction and therapy response (Journal article)

    Bentham, R., Litchfield, K., Watkins, T. B. K., Lim, E. L., Rosenthal, R., Martínez-Ruiz, C., . . . McGranahan, N. (2021). Using DNA sequencing data to quantify T cell fraction and therapy response. Nature, 597(7877), 555-560. doi:10.1038/s41586-021-03894-5

    DOI: 10.1038/s41586-021-03894-5

    CD8 T-cell-mediated cerebellitis directed against Purkinje cell antigen after ipilimumab for small cell lung cancer (Journal article)

    Hardwick, M., Nolan, L., Nicoll, J. A. R., Jogai, S., Arriola, E., Joseph-Pietras, D., . . . Galea, I. (2021). CD8 T-cell-mediated cerebellitis directed against Purkinje cell antigen after ipilimumab for small cell lung cancer. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY. doi:10.1111/nan.12755

    DOI: 10.1111/nan.12755

    Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy (Journal article)

    Eschweiler, S., Clarke, J., Ramirez-Suastegui, C., Panwar, B., Madrigal, A., Chee, S. J., . . . Vijayanand, P. (2021). Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy. NATURE IMMUNOLOGY, 22(8), 1052-+. doi:10.1038/s41590-021-00958-6

    DOI: 10.1038/s41590-021-00958-6

    Early-Phase Interventional Trials in Oral Cancer Prevention (Journal article)

    McCarthy, C., Fedele, S., Ottensmeier, C., & Shaw, R. J. (2021). Early-Phase Interventional Trials in Oral Cancer Prevention. CANCERS, 13(15). doi:10.3390/cancers13153845

    DOI: 10.3390/cancers13153845

    The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. (Journal article)

    Coen, O., Corrie, P., Marshall, H., Plummer, R., Ottensmeier, C., Hook, J., . . . Danson, S. (2021). The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma.. BMC cancer, 21(1), 761. doi:10.1186/s12885-021-08509-w

    DOI: 10.1186/s12885-021-08509-w

    Analysis of Immune Landscape in Pancreatic and Ileal Neuroendocrine Tumours Demonstrates an Immune Cold Tumour Microenvironment (Journal article)

    Tanno, L., Naheed, S., Dunbar, J., Tod, J., Lopez, M. A., Taylor, J., . . . Ottensmeier, C. H. (2021). Analysis of Immune Landscape in Pancreatic and Ileal Neuroendocrine Tumours Demonstrates an Immune Cold Tumour Microenvironment. NEUROENDOCRINOLOGY. doi:10.1159/000517688

    DOI: 10.1159/000517688

    Prospective longitudinal study of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC) (Journal article)

    von Witzleben, A., Fehn, A., Grages, A., Ezic, J., Jeske, S. S., Puntigam, L. K., . . . Laban, S. (2021). Prospective longitudinal study of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC). INTERNATIONAL JOURNAL OF CANCER, 148(8), 2023-2035. doi:10.1002/ijc.33446

    DOI: 10.1002/ijc.33446

    Melanoma-reactive T cells take up residence (Journal article)

    Ganesan, A. -P., & Ottensmeier, C. H. H. (2021). Melanoma-reactive T cells take up residence. Nature Cancer, 2(3), 253-255. doi:10.1038/s43018-021-00189-6

    DOI: 10.1038/s43018-021-00189-6

    Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC. (Journal article)

    von Witzleben, A., Currall, E., Wood, O., Chudley, L., Akinyegun, O., Thomas, J., . . . Ottensmeier, C. H. (2021). Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC.. Frontiers in Oncology, 10, 591063. doi:10.3389/fonc.2020.591063

    DOI: 10.3389/fonc.2020.591063

    Severely ill COVID-19 patients display impaired exhaustion features in SARS-CoV-2-reactive CD8(+) T cells (Journal article)

    Kusnadi, A., Ramirez-Suastegui, C., Fajardo, V., Chee, S. J., Meckiff, B. J., Simon, H., . . . Ottensmeier, C. H. (2021). Severely ill COVID-19 patients display impaired exhaustion features in SARS-CoV-2-reactive CD8(+) T cells. SCIENCE IMMUNOLOGY, 6(55). doi:10.1126/sciimmunol.abe4782

    DOI: 10.1126/sciimmunol.abe4782

    2020

    Novel players: tissue-resident memory B cells (Journal article)

    Savelyeva, N., & Ottensmeier, C. H. (2020). Novel players: tissue-resident memory B cells. BLOOD, 136(24), 2722-2723. doi:10.1182/blood.2020007890

    DOI: 10.1182/blood.2020007890

    COVID-19 genetic risk variants are associated with expression of multiple genes in diverse immune cell types (Journal article)

    Schmiedel, B. J., Chandra, V., Rocha, J., Gonzalez-Colin, C., Bhattacharyya, S., Madrigal, A., . . . Vijayanand, P. (n.d.). COVID-19 genetic risk variants are associated with expression of multiple genes in diverse immune cell types. doi:10.1101/2020.12.01.407429

    DOI: 10.1101/2020.12.01.407429

    Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19 (Journal article)

    Meckiff, B. J., Ramirez-Suastegui, C., Fajardo, V., Chee, S. J., Kusnadi, A., Simon, H., . . . Vijayanand, P. (2020). Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19. Cell, 183(5), 1340-1353. doi:10.1016/j.cell.2020.10.001

    DOI: 10.1016/j.cell.2020.10.001

    CTEN Induces Tumour Cell Invasion and Survival and Is Prognostic in Radiotherapy-Treated Head and Neck Cancer (Journal article)

    Fleming, J. C., Woo, J., Moutasim, K., Hanley, C. J., Frampton, S. J., Wood, O., . . . Thomas, G. J. (2020). CTEN Induces Tumour Cell Invasion and Survival and Is Prognostic in Radiotherapy-Treated Head and Neck Cancer. CANCERS, 12(10). doi:10.3390/cancers12102963

    DOI: 10.3390/cancers12102963

    HNSCC: Tumour Antigens and Their Targeting by Immunotherapy (Journal article)

    von Witzleben, A., Wang, C., Laban, S., Savelyeva, N., & Ottensmeier, C. H. (2020). HNSCC: Tumour Antigens and Their Targeting by Immunotherapy. CELLS, 9(9). doi:10.3390/cells9092103

    DOI: 10.3390/cells9092103

    CyTOF mass cytometry reveals phenotypically distinct human blood neutrophil populations differentially correlated with melanoma stage (Journal article)

    Zhu, Y. P., Eggert, T., Araujo, D. J., Vijayanand, P., Ottensmeier, C. H., & Hedrick, C. C. (2020). CyTOF mass cytometry reveals phenotypically distinct human blood neutrophil populations differentially correlated with melanoma stage. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 8(2). doi:10.1136/jitc-2019-000473

    DOI: 10.1136/jitc-2019-000473

    Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial (Journal article)

    Middleton, G., Brock, K., Savage, J., Mant, R., Summers, Y., Connibear, J., . . . Billingham, L. (2020). Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. The Lancet Respiratory Medicine, 8(9), 895-904. doi:10.1016/S2213-2600(20)30033-3

    DOI: 10.1016/S2213-2600(20)30033-3

    M1(hot)tumor-associated macrophages boost tissue-resident memory T cells infiltration and survival in human lung cancer (Journal article)

    Garrido-Martin, E. M., Mellows, T. W. P., Clarke, J., Ganesan, A. -P., Wood, O., Cazaly, A., . . . Sanchez-Elsner, T. (2020). M1(hot)tumor-associated macrophages boost tissue-resident memory T cells infiltration and survival in human lung cancer. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 8(2). doi:10.1136/jitc-2020-000778

    DOI: 10.1136/jitc-2020-000778

    Severely ill COVID-19 patients display augmented functional properties in SARS-CoV-2-reactive CD8 + T cells. (Journal article)

    Kusnadi, A., Ramírez-Suástegui, C., Fajardo, V., Chee, S. J., Meckiff, B. J., Simon, H., . . . Ottensmeier, C. H. (2020). Severely ill COVID-19 patients display augmented functional properties in SARS-CoV-2-reactive CD8 + T cells.. bioRxiv. doi:10.1101/2020.07.09.194027

    DOI: 10.1101/2020.07.09.194027

    Single-Cell Transcriptomic Analysis of SARS-CoV-2 Reactive CD4 + T Cells. (Journal article)

    Meckiff, B. J., Ramírez-Suástegui, C., Fajardo, V., Chee, S. J., Kusnadi, A., Simon, H., . . . Vijayanand, P. (2020). Single-Cell Transcriptomic Analysis of SARS-CoV-2 Reactive CD4 + T Cells.. SSRN, 3641939. doi:10.2139/ssrn.3641939

    DOI: 10.2139/ssrn.3641939

    A clonal expression biomarker associates with lung cancer mortality (vol 25, pg 1540, 2019) (Journal article)

    Biswas, D., Birkbak, N. J., Rosenthal, R., Hiley, C. T., Lim, E. L., Papp, K., . . . Consortium, T. (2020). A clonal expression biomarker associates with lung cancer mortality (vol 25, pg 1540, 2019). NATURE MEDICINE, 26(7), 1148. doi:10.1038/s41591-020-0899-z

    DOI: 10.1038/s41591-020-0899-z

    Geospatial immune variability illuminates differential evolution of lung adenocarcinoma (Journal article)

    AbdulJabbar, K., Raza, S. E. A., Rosenthal, R., Jamal-Hanjani, M., Veeriah, S., Akarca, A., . . . Consortium, T. (2020). Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. NATURE MEDICINE, 26(7), 1054-+. doi:10.1038/s41591-020-0900-x

    DOI: 10.1038/s41591-020-0900-x

    Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse (vol 25, pg 1534, 2019) (Journal article)

    Chemi, F., Rothwell, D. G., McGranahan, N., Gulati, S., Abbosh, C., Pearce, S. P., . . . Consortium, T. (2020). Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse (vol 25, pg 1534, 2019). NATURE MEDICINE, 26(7), 1147. doi:10.1038/s41591-020-0865-9

    DOI: 10.1038/s41591-020-0865-9

    Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer (vol 25, pg1549, 2019) (Journal article)

    Joshi, K., de Massy, M. R., Ismail, M., Reading, J. L., Uddin, I., Woolston, A., . . . Consortium, T. (2020). Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer (vol 25, pg1549, 2019). NATURE MEDICINE, 26(7), 1148. doi:10.1038/s41591-020-0866-8

    DOI: 10.1038/s41591-020-0866-8

    Paracrine SPARC signaling dysregulates alveolar epithelial barrier integrity and function in lung fibrosis (Journal article)

    Conforti, F., Ridley, R., Brereton, C., Alzetani, A., Johnson, B., Marshall, B. G., . . . Davies, D. E. (2020). Paracrine SPARC signaling dysregulates alveolar epithelial barrier integrity and function in lung fibrosis. CELL DEATH DISCOVERY, 6(1). doi:10.1038/s41420-020-0289-9

    DOI: 10.1038/s41420-020-0289-9

    Single-cell transcriptomic analysis of SARS-CoV-2 reactive CD4+T cells (Journal article)

    Meckiff, B. J., Ramírez-Suástegui, C., Fajardo, V., Chee, S. J., Kusnadi, A., Simon, H., . . . Vijayanand, P. (n.d.). Single-cell transcriptomic analysis of SARS-CoV-2 reactive CD4+T cells. doi:10.1101/2020.06.12.148916

    DOI: 10.1101/2020.06.12.148916

    Spatially discrete signalling niches regulate fibroblast heterogeneity in human lung cancer (Journal article)

    Hanley, C. J., Waise, S., Parker, R., Lopez, M. A., Taylor, J., Kimbley, L. M., . . . Thomas, G. J. (2020). Spatially discrete signalling niches regulate fibroblast heterogeneity in human lung cancer. doi:10.1101/2020.06.08.134270

    DOI: 10.1101/2020.06.08.134270

    Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue (Journal article)

    Litchfield, K., Stanislaw, S., Spain, L., Gallegos, L. L., Rowan, A., Schnidrig, D., . . . Consortium, P. E. A. C. E. (2020). Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. CELL REPORTS, 31(5). doi:10.1016/j.celrep.2020.107550

    DOI: 10.1016/j.celrep.2020.107550

    NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors (Journal article)

    Ford, K., Hanley, C. J., Mellone, M., Szyndralewiez, C., Heitz, F., Wiesel, P., . . . Thomas, G. J. (2020). NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors. CANCER RESEARCH, 80(9), 1846-1860. doi:10.1158/0008-5472.CAN-19-3158

    DOI: 10.1158/0008-5472.CAN-19-3158

    Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma (Journal article)

    Cebon, J. S., Gore, M., Thompson, J. F., Davis, I. D., McArthur, G. A., Walpole, E., . . . Chen, W. (2020). Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 8(1). doi:10.1136/jitc-2019-000410

    DOI: 10.1136/jitc-2019-000410

    Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation? (Journal article)

    Masterson, L., Howard, J., Gonzalez-Cruz, J., Jackson, C., Barnett, C., Overton, L., . . . Lechner, M. (2020). Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?. INTERNATIONAL JOURNAL OF CANCER, 146(8), 2305-2314. doi:10.1002/ijc.32869

    DOI: 10.1002/ijc.32869

    Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution (Journal article)

    Lopez, S., Lim, E. L., Horswell, S., Haase, K., Huebner, A., Dietzen, M., . . . Consortium, T. (2020). Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution. NATURE GENETICS, 52(3), 283-+. doi:10.1038/s41588-020-0584-7

    DOI: 10.1038/s41588-020-0584-7

    Single-Cell Analysis of Cancer-Associated Fibroblast Heterogeneity in Non-Small Cell Lung Cancer: Relating Molecular Phenotype to Function (Conference Paper)

    Waise, S., Hanley, C. J., Parker, R., Ottensmeier, C. H., Rose-Zerilli, M. J. J., & Thomas, G. J. (2020). Single-Cell Analysis of Cancer-Associated Fibroblast Heterogeneity in Non-Small Cell Lung Cancer: Relating Molecular Phenotype to Function. In JOURNAL OF PATHOLOGY Vol. 250 (pp. 9). Retrieved from http://gateway.webofknowledge.com/

    Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-alpha (Journal article)

    Tezera, L. B., Bielecka, M. K., Ogongo, P., Walker, N. F., Ellis, M., Garay-Baquero, D. J., . . . Elkington, P. T. (2020). Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-alpha. ELIFE, 9. doi:10.7554/eLife.52668

    DOI: 10.7554/eLife.52668

    Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future (Chapter)

    Gouttefangeas, C., Walter, S., Welters, M. J. P., Ottensmeier, C., van der Burg, S. H., & Chan, C. (2020). Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future. In Cancer Immunology (pp. 761-783). Springer International Publishing. doi:10.1007/978-3-030-30845-2_33

    DOI: 10.1007/978-3-030-30845-2_33

    2019

    Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial (vol 29, pg 1843, 2018) (Journal article)

    Corrie, P. G., Marshall, A., Nathan, P. D., Lorigan, P., Gore, M., Tahir, S., . . . Investigators, A. V. A. S. T. -M. (2019). Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial (vol 29, pg 1843, 2018). ANNALS OF ONCOLOGY, 30(12), 2013-2014. doi:10.1093/annonc/mdz237

    DOI: 10.1093/annonc/mdz237

    CyTOF reveals phenotypically-distinct human blood neutrophil populations differentially correlated with melanoma stage (Journal article)

    Zhu, Y. P., Eggert, T., Araujo, D., Vijayanand, P., Ottensmeier, C., & Hedrick, C. (2019). CyTOF reveals phenotypically-distinct human blood neutrophil populations differentially correlated with melanoma stage. doi:10.1101/826644

    DOI: 10.1101/826644

    A clonal expression biomarker associates with lung cancer mortality (Journal article)

    Biswas, D., Birkbak, N. J., Rosenthal, R., Hiley, C. T., Lim, E. L., Papp, K., . . . Consortium, T. (2019). A clonal expression biomarker associates with lung cancer mortality. NATURE MEDICINE, 25(10), 1540-+. doi:10.1038/s41591-019-0595-z

    DOI: 10.1038/s41591-019-0595-z

    Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse (Journal article)

    Chemi, F., Rothwell, D. G., McGranahan, N., Gulati, S., Abbosh, C., Pearce, S. P., . . . Consortium, T. (2019). Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. NATURE MEDICINE, 25(10), 1534-+. doi:10.1038/s41591-019-0593-1

    DOI: 10.1038/s41591-019-0593-1

    Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer (Journal article)

    Joshi, K., de Massy, M. R., Ismail, M., Reading, J. L., Uddin, I., Woolston, A., . . . Consortium, T. (2019). Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. NATURE MEDICINE, 25(10), 1549-+. doi:10.1038/s41591-019-0592-2

    DOI: 10.1038/s41591-019-0592-2

    A randomised phase III multicentre trial to evaluate the duration of anti-PD1 monoclonal antibody monotherapy in patients with metastatic melanoma (DANTE) - Stage 1 Results (Conference Paper)

    Danson, S., Plummer, R., Ottensmeier, C., Hook, J., Marshall, H., Sagoo, G., . . . Corrie, P. (2019). A randomised phase III multicentre trial to evaluate the duration of anti-PD1 monoclonal antibody monotherapy in patients with metastatic melanoma (DANTE) - Stage 1 Results. In BRITISH JOURNAL OF CANCER Vol. 121 (pp. 23). Retrieved from http://gateway.webofknowledge.com/

    Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer (Journal article)

    Clarke, J., Panwar, B., Madrigal, A., Singh, D., Gujar, R., Wood, O., . . . Vijayanand, P. (2019). Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer. JOURNAL OF EXPERIMENTAL MEDICINE, 216(9), 2128-2149. doi:10.1084/jem.20190249

    DOI: 10.1084/jem.20190249

    The utility of Ki-67 as a prognostic biomarker in pulmonary neuroendocrine tumours: protocol for a systematic review and meta-analysis (Journal article)

    Naheed, S., Holden, C., Tanno, L., Jaynes, E., Cave, J., Ottensmeier, C. H., & Pelosi, G. (2019). The utility of Ki-67 as a prognostic biomarker in pulmonary neuroendocrine tumours: protocol for a systematic review and meta-analysis. BMJ OPEN, 9(8). doi:10.1136/bmjopen-2019-031531

    DOI: 10.1136/bmjopen-2019-031531

    Autophagy inhibition-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis (Journal article)

    Hill, C., Li, J., Liu, D., Conforti, F., Brereton, C. J., Yao, L., . . . Wang, Y. (2019). Autophagy inhibition-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis. CELL DEATH & DISEASE, 10. doi:10.1038/s41419-019-1820-x

    DOI: 10.1038/s41419-019-1820-x

    Importance of the immune system in head and neck cancer (Journal article)

    Mirza, A. H., Thomas, G., Ottensmeier, C. H., & King, E. V. (2019). Importance of the immune system in head and neck cancer. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 41(8), 2789-2800. doi:10.1002/hed.25716

    DOI: 10.1002/hed.25716

    An optimised tissue disaggregation and data processing pipeline for characterising fibroblast phenotypes using single-cell RNA sequencing (Journal article)

    Waise, S., Parker, R., Rose-Zerilli, M. J. J., Layfield, D. M., Wood, O., West, J., . . . Hanley, C. J. (2019). An optimised tissue disaggregation and data processing pipeline for characterising fibroblast phenotypes using single-cell RNA sequencing. SCIENTIFIC REPORTS, 9. doi:10.1038/s41598-019-45842-4

    DOI: 10.1038/s41598-019-45842-4

    Combination immunotherapy successfully control tumor growth in a transgenic mouse model (Conference Paper)

    Lim, K. P., Zainal, S., Zulaziz, N., Gan, C. P., Chai, S. J., Lye, B. K. W., . . . Cheong, S. C. (2019). Combination immunotherapy successfully control tumor growth in a transgenic mouse model. In CANCER RESEARCH Vol. 79. doi:10.1158/1538-7445.AM2019-1466

    DOI: 10.1158/1538-7445.AM2019-1466

    Single-cell analysis of cancer-associated fibroblast heterogeneity in non-small cell lung cancer: Mapping molecular phenotypes in tumors (Conference Paper)

    Waise, S., Hanley, C. J., Parker, R., Ottensmeier, C. H., Rose-Zerilli, M., & Thomas, G. J. (2019). Single-cell analysis of cancer-associated fibroblast heterogeneity in non-small cell lung cancer: Mapping molecular phenotypes in tumors. In CANCER RESEARCH Vol. 79. doi:10.1158/1538-7445.AM2019-3762

    DOI: 10.1158/1538-7445.AM2019-3762

    Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer (Journal article)

    Hardy-Werbin, M., Rocha, P., Arpi, O., Taus, A., Nonell, L., Duran, X., . . . Arriola, E. (2019). Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer. ONCOIMMUNOLOGY, 8(6). doi:10.1080/2162402X.2019.1593810

    DOI: 10.1080/2162402X.2019.1593810

    Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma. (Retraction of Vol 17, Pg 2132, 2018) (Journal article)

    Shraibman, B., Barnea, E., Kadosh, D. M., Haimovich, Y., Slobodin, G., Rosner, I., . . . Admon, A. (2019). Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma. (Retraction of Vol 17, Pg 2132, 2018). MOLECULAR & CELLULAR PROTEOMICS, 18(6), 1270. doi:10.1074/mcp.W119.001571

    DOI: 10.1074/mcp.W119.001571

    Paracrine signalling during ZEB1-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in lung fibrosis (Journal article)

    Yao, L., Conforti, F., Hill, C., Bell, J., Drawater, L., Li, J., . . . Wang, Y. (2019). Paracrine signalling during ZEB1-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in lung fibrosis. CELL DEATH AND DIFFERENTIATION, 26(5), 943-957. doi:10.1038/s41418-018-0175-7

    DOI: 10.1038/s41418-018-0175-7

    Recent advances in the molecular landscape of lung neuroendocrine tumors (Journal article)

    Pelosi, G., Bianchi, F., Hofman, P., Pattini, L., Stroebel, P., Calabrese, F., . . . Ottensmeier, C. H. (2019). Recent advances in the molecular landscape of lung neuroendocrine tumors. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 19(4), 281-297. doi:10.1080/14737159.2019.1595593

    DOI: 10.1080/14737159.2019.1595593

    Investigating the Mechanisms Underlying Tumour Immune Evasion in Head and Neck Squamous Cell Carcinoma (Conference Paper)

    Robinson, H., Fleming, J. C., Thirdborough, S., Ottensmeier, C., Thomas, G. J., & Moutasim, K. A. (2019). Investigating the Mechanisms Underlying Tumour Immune Evasion in Head and Neck Squamous Cell Carcinoma. In JOURNAL OF PATHOLOGY Vol. 248 (pp. S18). Retrieved from http://gateway.webofknowledge.com/

    Neoantigen-directed immune escape in lung cancer evolution (Journal article)

    Rosenthal, R., Cadieux, E. L., Salgado, R., Al Bakir, M., Moore, D. A., Hiley, C. T., . . . Consortium, T. (2019). Neoantigen-directed immune escape in lung cancer evolution. NATURE, 567(7749), 479-+. doi:10.1038/s41586-019-1032-7

    DOI: 10.1038/s41586-019-1032-7

    Actively personalized vaccination trial for newly diagnosed glioblastoma (vol 565, pg 240, 2018) (Journal article)

    Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanovic, S., Gouttefangeas, C., . . . Wick, W. (2019). Actively personalized vaccination trial for newly diagnosed glioblastoma (vol 565, pg 240, 2018). NATURE, 566(7745), E13. doi:10.1038/s41586-019-0959-z

    DOI: 10.1038/s41586-019-0959-z

    Recurrent group A Streptococcus tonsillitis is an immunosusceptibility disease involving antibody deficiency and aberrant T-FH cells (Journal article)

    Dan, J. M., Havenar-Daughton, C., Kendric, K., Al-kolla, R., Kaushik, K., Rosales, S. L., . . . Crotty, S. (2019). Recurrent group A Streptococcus tonsillitis is an immunosusceptibility disease involving antibody deficiency and aberrant T-FH cells. Science Translational Medicine, 11(478). doi:10.1126/scitranslmed.aau3776

    DOI: 10.1126/scitranslmed.aau3776

    HPV, tumour metabolism and novel target identification in head and neck squamous cell carcinoma (Journal article)

    Fleming, J. C., Woo, J., Moutasim, K., Mellone, M., Frampton, S. J., Mead, A., . . . Thomas, G. J. (2019). HPV, tumour metabolism and novel target identification in head and neck squamous cell carcinoma. British Journal of Cancer, 120(3), 356-367. doi:10.1038/s41416-018-0364-7

    DOI: 10.1038/s41416-018-0364-7

    Immunomonitoring for actively personalized peptide vaccines (APVACs) during immunotherapeutic treatment of glioblastoma (Conference Paper)

    Ulges, A., Hilf, N., Wick, W., Platten, M., Dietrich, P. -Y., Frenzel, K., . . . Mendrzyk, R. (2019). Immunomonitoring for actively personalized peptide vaccines (APVACs) during immunotherapeutic treatment of glioblastoma. In CANCER IMMUNOLOGY RESEARCH Vol. 7. doi:10.1158/2326-6074.CRICIMTEATIAACR18-A020

    DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-A020

    Plant viral particle vaccine induces a potent antitumor response through induction of antigen-specific T-cells and overcoming an immunosuppressive tumor microenvironment (Conference Paper)

    Wang, C., Wang, Y., Allen, A. J., Jobsri, J., Thomas, G. J., Ottensmeier, C. H., & Savelyeva, N. (2019). Plant viral particle vaccine induces a potent antitumor response through induction of antigen-specific T-cells and overcoming an immunosuppressive tumor microenvironment. In CANCER IMMUNOLOGY RESEARCH Vol. 7. doi:10.1158/2326-6074.CRICIMTEATIAACR18-B139

    DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-B139

    Actively personalized vaccination trial for newly diagnosed glioblastoma (Journal article)

    Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanovic, S., Gouttefangeas, C., . . . Wick, W. (2019). Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature, 565(7738), 240-245. doi:10.1038/s41586-018-0810-y

    DOI: 10.1038/s41586-018-0810-y

    HPV Epitope Processing Differences Correlate with ERAP1 Allotype and Extent of CD8(+) T-cell Tumor Infiltration in OPSCC (Journal article)

    Reeves, E., Wood, O., Ottensmeier, C. H., King, E. V., Thomas, G. J., Elliott, T., & James, E. (2019). HPV Epitope Processing Differences Correlate with ERAP1 Allotype and Extent of CD8(+) T-cell Tumor Infiltration in OPSCC. CANCER IMMUNOLOGY RESEARCH, 7(7), 1202-1213. doi:10.1158/2326-6066.CIR-18-0498

    DOI: 10.1158/2326-6066.CIR-18-0498

    Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma (Journal article)

    Shraibman, B., Barnea, E., Kadosh, D. M., Haimovich, Y., Slobodin, G., Rosner, I., . . . Admon, A. (2019). Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. MOLECULAR & CELLULAR PROTEOMICS, 18(6), 1255-1268. doi:10.1074/mcp.RA119.001524

    DOI: 10.1074/mcp.RA119.001524

    2018

    Implications of Tuberculosis Reactivation after Immune Checkpoint Inhibition (Journal article)

    Elkington, P. T., Bateman, A. C., Thomas, G. J., & Ottensmeier, C. H. (2018). Implications of Tuberculosis Reactivation after Immune Checkpoint Inhibition. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 198(11), 1451-1453. doi:10.1164/rccm.201807-1250LE

    DOI: 10.1164/rccm.201807-1250LE

    ATIM-20. GAPVAC-101 TRIAL OF A HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (Journal article)

    Wick, W., Dietrich, P. -Y., HIlf, N., Platten, M., Frenzel, K., Admon, A., . . . Singh-Jasuja, H. (2018). ATIM-20. GAPVAC-101 TRIAL OF A HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-oncology, 20(Suppl 6), vi5.

    GAPVAC-101 TRIAL OF A HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (Conference Paper)

    Wick, W., Dietrich, P. -Y., Hilf, N., Platten, M., Frenzel, K., Admon, A., . . . Singh-Jasuja, H. (2018). GAPVAC-101 TRIAL OF A HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. In NEURO-ONCOLOGY Vol. 20 (pp. 5). Retrieved from http://gateway.webofknowledge.com/

    Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma (Retracted article. See vol. 18, pg. 1270, 2019) (Journal article)

    Shraibman, B., Barnea, E., Kadosh, D. M., Haimovich, Y., Slobodin, G., Rosner, I., . . . Admon, A. (2018). Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma (Retracted article. See vol. 18, pg. 1270, 2019). MOLECULAR & CELLULAR PROTEOMICS, 17(11), 2132-2145. doi:10.1074/mcp.RA118.000792

    DOI: 10.1074/mcp.RA118.000792

    CD103+CD8+Lymphocytes Characterize the Immune Infiltration in a Case With Pseudoprogression in Squamous NSCLC (Journal article)

    Rocha, P., Hardy-Werbin, M., Naranjo, D., Taus, A., Rodrigo, M., Zuccarino, F., . . . Arriola, E. (2018). CD103+CD8+Lymphocytes Characterize the Immune Infiltration in a Case With Pseudoprogression in Squamous NSCLC. JOURNAL OF THORACIC ONCOLOGY, 13(10), E193-E196. doi:10.1016/j.jtho.2018.05.008

    DOI: 10.1016/j.jtho.2018.05.008

    Immunotherapy in the immunodeficient: A treatment paradox? (Journal article)

    Campbell, N. J., Longley, J., Pascalis, A., Bennett, J., Remer, M., Stone, R., . . . Ottensmeier, C. (2018). Immunotherapy in the immunodeficient: A treatment paradox?. ANNALS OF ONCOLOGY, 29. Retrieved from http://gateway.webofknowledge.com/

    Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice (Journal article)

    Califano, R., Lal, R., Lewanski, C., Nicolson, M. C., Ottensmeier, C. H., Popat, S., . . . Postmus, P. E. (2018). Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice. FUTURE ONCOLOGY, 14(23), 2415-2431. doi:10.2217/fon-2018-0330

    DOI: 10.2217/fon-2018-0330

    Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial (Journal article)

    Middleton, G., Brock, K., Summers, Y., Connibear, J., Shah, R., Ottensmeier, C., . . . Billingham, L. (2018). Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial. ANNALS OF ONCOLOGY, 29, 497. Retrieved from http://gateway.webofknowledge.com/

    Exosomal microRNAs in the lung: eliciting long-term intercellular communication? (Conference Paper)

    Lekkas, A., Mellows, T., Garrido-Martin, M., Howarth, P. H., Friedmann, P. S., Vijayanand, P., . . . Sanchez-Elsner, T. (2018). Exosomal microRNAs in the lung: eliciting long-term intercellular communication?. In EUROPEAN RESPIRATORY JOURNAL Vol. 52. doi:10.1183/13993003.congress-2018.OA2118

    DOI: 10.1183/13993003.congress-2018.OA2118

    HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: THE GAPVAC TRIAL (Conference Paper)

    Dietrich, P., Wick, W., Hilf, N., Frenzel, K., Gouttefangeas, C., Platten, M., . . . Consortium, G. A. P. V. A. C. (2018). HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: THE GAPVAC TRIAL. In NEURO-ONCOLOGY Vol. 20 (pp. 219). Retrieved from http://gateway.webofknowledge.com/

    Liver pseudoprogression in advanced lung squamous cell carcinoma treated with nivolumab: histology and immunohistochemical profile (Conference Paper)

    Hans, D. N., Rocha, P., Arriola, E., Rodrigo, M. T., Ottensmeier, C. H., Iglesias, M., . . . Lloveras, B. (2018). Liver pseudoprogression in advanced lung squamous cell carcinoma treated with nivolumab: histology and immunohistochemical profile. In VIRCHOWS ARCHIV Vol. 473 (pp. S128). Retrieved from http://gateway.webofknowledge.com/

    OS2.2 Highly personalized peptide vaccination for patients with newly diagnosed glioblastoma: the GAPVAC trial (Journal article)

    Dietrich, P., Wick, W., Hilf, N., Frenzel, K., Gouttefangeas, C., Platten, M., . . . GAPVAC Consortium. (2018). OS2.2 Highly personalized peptide vaccination for patients with newly diagnosed glioblastoma: the GAPVAC trial. Neuro-oncology, 20(Suppl 3), iii219.

    Single-Cell Analysis of Cancer-Associated Fibroblast Heterogeneity in Non-Small Cell Lung Cancer: Mapping Molecular Phenotypes in Tumours (Conference Paper)

    Waise, S., Hanley, C. J., Parker, R., Ottensmeier, C. H., Rose-Zerilli, M. J., & Thomas, G. J. (2018). Single-Cell Analysis of Cancer-Associated Fibroblast Heterogeneity in Non-Small Cell Lung Cancer: Mapping Molecular Phenotypes in Tumours. In JOURNAL OF PATHOLOGY Vol. 246 (pp. S13). Retrieved from http://gateway.webofknowledge.com/

    Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial (Journal article)

    Corrie, P. G., Marshall, A., Nathan, P. D., Lorigan, P., Gore, M., Tahir, S., . . . Investigators, A. V. A. S. T. -M. (2018). Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. ANNALS OF ONCOLOGY, 29(8), 1843-1852. doi:10.1093/annonc/mdy229

    DOI: 10.1093/annonc/mdy229

    Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis (Journal article)

    Jones, M. G., Andriotis, O. G., Roberts, J. J. W., Lunn, K., Tear, V. J., Cao, L., . . . Davies, D. E. (2018). Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis. ELIFE, 7. doi:10.7554/eLife.36354

    DOI: 10.7554/eLife.36354

    Characterizing heterogeneity in the cancer-associated fibroblast population in non-small cell lung cancer: Relating phenotype to function (Conference Paper)

    Waise, S., Hanley, C., Parker, R., Rose-Zerilli, M., Ottensmeier, C., & Thomas, G. (2018). Characterizing heterogeneity in the cancer-associated fibroblast population in non-small cell lung cancer: Relating phenotype to function. In CANCER RESEARCH Vol. 78. doi:10.1158/1538-7445.AM2018-5084

    DOI: 10.1158/1538-7445.AM2018-5084

    Th1/Th2 and inflammatory cytokines as biomarkers of response to ipilimumab in small cell lung cancer (SCLC) patients (Conference Paper)

    Hardy-Werbin, M., Rocha, P., Arpi, O., Taus, A., Duran Jorda, X., Joseph-Pietras, D., . . . Arriola, E. (2018). Th1/Th2 and inflammatory cytokines as biomarkers of response to ipilimumab in small cell lung cancer (SCLC) patients. In CANCER RESEARCH Vol. 78. doi:10.1158/1538-7445.AM2018-LB-143

    DOI: 10.1158/1538-7445.AM2018-LB-143

    Evidence that recurrent Group A streptococcus tonsillitis is an immunosusceptibility disease involving antibody deficiency and aberrant Tfh cells (Journal article)

    Dan, J., Havenar-Daughton, C., Kendric, K., Kaushik, K., Rosales, S., Anderson, E., . . . Crotty, S. (2018). Evidence that recurrent Group A streptococcus tonsillitis is an immunosusceptibility disease involving antibody deficiency and aberrant Tfh cells. doi:10.1101/356741

    DOI: 10.1126/scitranslmed.aau3776

    Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial (Journal article)

    Patel, P. M., Ottensmeier, C. H., Mulatero, C., Lorigan, P., Plummer, R., Pandha, H., . . . Durrant, L. G. (2018). Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial. ONCOIMMUNOLOGY, 7(6). doi:10.1080/2162402X.2018.1433516

    DOI: 10.1080/2162402X.2018.1433516

    A randomised, double-blind, placebo-controlled phase IIa trial of AMG319 given orally as neoadjuvant therapy in patients with human papillomavirus (HPV) positive and negative head and neck squamous cell carcinoma (HNSCC). (Conference Paper)

    Ottensmeier, C. H. H., Jones, T., Sacco, J. J., McCaul, J. A., Brennan, P., Paterson, C., . . . King, E. (2018). A randomised, double-blind, placebo-controlled phase IIa trial of AMG319 given orally as neoadjuvant therapy in patients with human papillomavirus (HPV) positive and negative head and neck squamous cell carcinoma (HNSCC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36. doi:10.1200/JCO.2018.36.15_suppl.6068

    DOI: 10.1200/JCO.2018.36.15_suppl.6068

    CONFIRM: A phase III randomized trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma (Conference Paper)

    Fennell, D. A., Kirkpatrick, E. V., Cozens, K., Danson, S., Hanna, G. G., Lester, J. F., . . . Griffiths, G. (2018). CONFIRM: A phase III randomized trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36. doi:10.1200/JCO.2018.36.15_suppl.TPS8586

    DOI: 10.1200/JCO.2018.36.15_suppl.TPS8586

    GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma (Conference Paper)

    Wick, W., Dietrich, P. -Y., Kuttruff, S., Hilf, N., Frenzel, K., Admon, A., . . . Singh, H. (2018). GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36. doi:10.1200/JCO.2018.36.15_suppl.2000

    DOI: 10.1200/JCO.2018.36.15_suppl.2000

    Immunotherapy in metastatic melanoma: When is it safe to stop? (Conference Paper)

    Longley, J., Paschalis, A., Remer, M., Bennett, J., Muller, D. R., Stone, R., . . . Wheater, M. J. (2018). Immunotherapy in metastatic melanoma: When is it safe to stop?. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36. doi:10.1200/JCO.2018.36.15_suppl.e21518

    DOI: 10.1200/JCO.2018.36.15_suppl.e21518

    Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease (Journal article)

    Karydis, I., Gangi, A., Wheater, M. J., Choi, J., Wilson, I., Thomas, K., . . . Ottensmeier, C. (2018). Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease. JOURNAL OF SURGICAL ONCOLOGY, 117(6), 1170-1178. doi:10.1002/jso.24956

    DOI: 10.1002/jso.24956

    CONFIRM: a double-blind, placebo controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial (Journal article)

    Fennell, D. A., Kirkpatrick, E., Cozens, K., Nye, M., Lester, J., Hanna, G., . . . Griffiths, G. (2018). CONFIRM: a double-blind, placebo controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. TRIALS, 19. doi:10.1186/s13063-018-2602-y

    DOI: 10.1186/s13063-018-2602-y

    Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies (Journal article)

    Vargas, F. A., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., . . . Consortia, T. L. (2018). Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. CANCER CELL, 33(4), 649-+. doi:10.1016/j.ccell.2018.02.010

    DOI: 10.1016/j.ccell.2018.02.010

    Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model (Journal article)

    Allen, A., Wang, C., Caproni, L. J., Sugiyarto, G., Harden, E., Douglas, L. R., . . . Savelyeva, N. (2018). Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model. CANCER IMMUNOLOGY IMMUNOTHERAPY, 67(4), 627-638. doi:10.1007/s00262-017-2111-y

    DOI: 10.1007/s00262-017-2111-y

    Validation of Immunomonitoring Methods for Application in Clinical Studies: The HLA-Peptide Multimer Staining Assay (Journal article)

    Chandran, P. A., Laske, K., Cazaly, A., Rusch, E., Schmid-Horch, B., Rammensee, H. -G., . . . Gouttefangeas, C. (2018). Validation of Immunomonitoring Methods for Application in Clinical Studies: The HLA-Peptide Multimer Staining Assay. CYTOMETRY PART B-CLINICAL CYTOMETRY, 94(2), 342-353. doi:10.1002/cyto.b.21397

    DOI: 10.1002/cyto.b.21397

    Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab (Journal article)

    Hardy-Werbin, M., Arpi, O., Taus, A., Rocha, P., Joseph-Pietras, D., Nolan, L., . . . Arriola, E. (2018). Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab. ONCOIMMUNOLOGY, 7(2). doi:10.1080/2162402X.2017.1395125

    DOI: 10.1080/2162402X.2017.1395125

    BILATERAL METASTATIC CUTANEOUS MELANOMA TO RETINA AND VITREOUS AFTER IPILIMUMAB TREATED WITH PARS PLANA VITRECTOMY AND RADIOTHERAPY. (Journal article)

    Kanavati, S., Ottensmeier, C., Foria, V., & Krishnan, R. (2018). BILATERAL METASTATIC CUTANEOUS MELANOMA TO RETINA AND VITREOUS AFTER IPILIMUMAB TREATED WITH PARS PLANA VITRECTOMY AND RADIOTHERAPY.. Retinal cases & brief reports, 12(3), 184-187. doi:10.1097/icb.0000000000000477

    DOI: 10.1097/icb.0000000000000477

    CONFIRM: a phase III randomised trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma (Conference Paper)

    Hanna, G., Griffiths, G., Kirkpatrick, E. V., Cozens, K., Kalevras, M., Maishman, T., . . . Fennell, D. (2018). CONFIRM: a phase III randomised trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma. In LUNG CANCER Vol. 115 (pp. S84). doi:10.1016/S0169-5002(18)30216-2

    DOI: 10.1016/S0169-5002(18)30216-2

    Emerging role of clinical trials assistants (CTAs) - integrating clinical research into standard care (Conference Paper)

    Fixmer, C., Lane, M., Johnson, B., Chee, S., Walters, J., & Ottensmeier, C. (2018). Emerging role of clinical trials assistants (CTAs) - integrating clinical research into standard care. In LUNG CANCER Vol. 115 (pp. S14-S15). doi:10.1016/S0169-5002(18)30061-8

    DOI: 10.1016/S0169-5002(18)30061-8

    Real-world use of anti-PD-1 checkpoint inhibitors in the management of non-small cell lung cancer: experience from a large UK teaching hospital (Conference Paper)

    Remer, M., Muller, D., Cave, J., Nolan, L., Fenton, P., Bates, A. T., . . . Ottensmeier, C. (2018). Real-world use of anti-PD-1 checkpoint inhibitors in the management of non-small cell lung cancer: experience from a large UK teaching hospital. In LUNG CANCER Vol. 115 (pp. S35). doi:10.1016/S0169-5002(18)30111-9

    DOI: 10.1016/S0169-5002(18)30111-9

    Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4 (Journal article)

    Hanley, C. J., Mellone, M., Ford, K., Thirdborough, S. M., Mellows, T., Frampton, S. J., . . . Thomas, G. J. (2018). Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 110(1). doi:10.1093/jnci/djx121

    DOI: 10.1093/jnci/djx121

    2017

    Head and Neck Squamous Cell Carcinomas Are Characterized by a Stable Immune Signature Within the Primary Tumor Over Time and Space (Journal article)

    Wood, O., Clarke, J., Woo, J., Mirza, A. H., Woelk, C. H., Thomas, G. J., . . . Ottensmeier, C. H. (2017). Head and Neck Squamous Cell Carcinomas Are Characterized by a Stable Immune Signature Within the Primary Tumor Over Time and Space. CLINICAL CANCER RESEARCH, 23(24), 7641-7649. doi:10.1158/1078-0432.CCR-17-0373

    DOI: 10.1158/1078-0432.CCR-17-0373

    COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-deloss (Journal article)

    Crabb, S. J., Martin, K., Abab, J., Ratcliffe, I., Thornton, R., Lineton, B., . . . King, E. (2017). COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-deloss. EUROPEAN JOURNAL OF CANCER, 87, 75-83. doi:10.1016/j.ejca.2017.09.033

    DOI: 10.1016/j.ejca.2017.09.033

    Towards personalised medicine in lung and thymus neuroendocrine tumours (Journal article)

    Pelosi, G., Cave, J., & Ottensmeier, C. H. (2017). Towards personalised medicine in lung and thymus neuroendocrine tumours. LANCET ONCOLOGY, 18(12), 1563-1565. doi:10.1016/S1470-2045(17)30784-2

    DOI: 10.1016/S1470-2045(17)30784-2

    Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution (Journal article)

    McGranahan, N., Rosenthal, R., Hiley, C. T., Rowan, A. J., Watkins, T. B. K., Wilson, G. A., . . . Consortium, T. (2017). Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. CELL, 171(6), 1259-+. doi:10.1016/j.cell.2017.10.001

    DOI: 10.1016/j.cell.2017.10.001

    Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma (Journal article)

    Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., . . . Collaborators, C. . (2017). Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. NEW ENGLAND JOURNAL OF MEDICINE, 377(19), 1824-1835. doi:10.1056/NEJMoa1709030

    DOI: 10.1056/NEJMoa1709030

    AST-VAC2: An allogeneic dendritic cell cancer immunotherapy entering clinical trials in patients with lung cancer in the advanced and adjuvant setting (Conference Paper)

    Ottensmeier, C., Farmer-Hall, H., Acton, G., Lentfer, H., Nishimoto, K., Shoukat-Mumtaz, U., . . . Lebkowski, J. (2017). AST-VAC2: An allogeneic dendritic cell cancer immunotherapy entering clinical trials in patients with lung cancer in the advanced and adjuvant setting. In JOURNAL FOR IMMUNOTHERAPY OF CANCER Vol. 5. Retrieved from http://gateway.webofknowledge.com/

    CONFIRM: A Phase III Randomized Trial to Evaluate the Efficacy of Nivolumab versus Placebo in Relapsed Mesothelioma (Conference Paper)

    Fennell, D., Kirkpatrick, E., Cozens, K., Danson, S., Hanna, G., Lester, J., . . . Griffiths, G. (2017). CONFIRM: A Phase III Randomized Trial to Evaluate the Efficacy of Nivolumab versus Placebo in Relapsed Mesothelioma. In JOURNAL OF THORACIC ONCOLOGY Vol. 12 (pp. S2376). doi:10.1016/j.jtho.2017.09.1898

    DOI: 10.1016/j.jtho.2017.09.1898

    Ipilimumab Increases Th1/Th2 and Inflammatory Cytokines Counteracting Chemotherapy Effects in Small Cell Lung Cancer (Conference Paper)

    Hardy-Werbin, M., Rocha, P., Arpi, O., Taus, A., Joseph-Pietras, D., Rovira, A., . . . Arriola, E. (2017). Ipilimumab Increases Th1/Th2 and Inflammatory Cytokines Counteracting Chemotherapy Effects in Small Cell Lung Cancer. In JOURNAL OF THORACIC ONCOLOGY Vol. 12 (pp. S2042). Retrieved from http://gateway.webofknowledge.com/

    Evaluating the effect of immune cells on the outcome of patients with mesothelioma (Journal article)

    Chee, S. J., Lopez, M., Mellows, T., Gankande, S., Moutasim, K. A., Harris, S., . . . Ottensmeier, C. H. (2017). Evaluating the effect of immune cells on the outcome of patients with mesothelioma. BRITISH JOURNAL OF CANCER, 117(9), 1341-1348. doi:10.1038/bjc.2017.269

    DOI: 10.1038/bjc.2017.269

    FAK-PD1: a phase I/IIa trial of FAK (defactinib) & PD-1 (pembrolizumab) inhibition (Conference Paper)

    Symeonides, S., Evans, T. R. J., Coyle, V., Serrels, A., Thomson, F., Currie, D., . . . Ottensmeier, C. (2017). FAK-PD1: a phase I/IIa trial of FAK (defactinib) & PD-1 (pembrolizumab) inhibition. In ANNALS OF ONCOLOGY Vol. 28. Retrieved from http://gateway.webofknowledge.com/

    Transcriptomic profiling reveals M1-high tumour associated macrophages that orchestrate the adaptive Anti-tumour response in human lung cancer (Conference Paper)

    Garrido-Martin, E. M., Ottensmeier, C., Vijayanand, P., & Sanchez-Elsner, T. (2017). Transcriptomic profiling reveals M1-high tumour associated macrophages that orchestrate the adaptive Anti-tumour response in human lung cancer. In EUROPEAN RESPIRATORY JOURNAL Vol. 50. doi:10.1183/1393003.congress-2017.PA4951

    DOI: 10.1183/1393003.congress-2017.PA4951

    Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer (Journal article)

    Ganesan, A. -P., Clarke, J., Wood, O., Garrido-Martin, E. M., Chee, S. J., Mellows, T., . . . Ottensmeier, C. H. (2017). Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. Nature Immunology, 18(8), 940-950. doi:10.1038/ni.3775

    DOI: 10.1038/ni.3775

    A distinct CD8(+) tumor infiltrating lymphocyte subset is associated with high TIL density, enhanced cytotoxicity and improved survival in patients with lung cancer (Conference Paper)

    Ganesan, A. P., Wood, O., Garrido-Martin, E., Chee, S., Mellows, T., Clarke, J., . . . Ottensmeier, C. H. (2017). A distinct CD8(+) tumor infiltrating lymphocyte subset is associated with high TIL density, enhanced cytotoxicity and improved survival in patients with lung cancer. In CANCER RESEARCH Vol. 77. doi:10.1158/1538-7445.AM2017-2948

    DOI: 10.1158/1538-7445.AM2017-2948

    Tracking the Evolution of Non-Small-Cell Lung Cancer (Journal article)

    Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., . . . Consortium, T. (2017). Tracking the Evolution of Non-Small-Cell Lung Cancer. NEW ENGLAND JOURNAL OF MEDICINE, 376(22), 2109-2121. doi:10.1056/NEJMoa1616288

    DOI: 10.1056/NEJMoa1616288

    Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution (Journal article)

    Abbosh, C., Birkbak, N. J., Wilson, G. A., Jamal-Hanjani, M., Constantin, T., Salari, R., . . . Consortium, T. P. E. A. C. E. (2017). Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. NATURE, 545(7655), 446-+. doi:10.1038/nature22364

    DOI: 10.1038/nature22364

    Deciphering antitumour response and resistance with intratumour heterogeneity (DARWIN II). (Conference Paper)

    Hiley, C. T., Ahmad, T., Jamal-Hanjani, M., Abbosh, C., Ngai, V., Hackshaw, A., . . . Swanton, C. (2017). Deciphering antitumour response and resistance with intratumour heterogeneity (DARWIN II).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35. doi:10.1200/JCO.2017.35.15_suppl.TPS9099

    DOI: 10.1200/JCO.2017.35.15_suppl.TPS9099

    Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR) (Journal article)

    Seckl, M. J., Ottensmeier, C. H., Cullen, M., Schmid, P., Ngai, Y., Muthukumar, D., . . . Hackshaw, A. (2017). Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR). JOURNAL OF CLINICAL ONCOLOGY, 35(14), 1506-+. doi:10.1200/JCO.2016.69.7391

    DOI: 10.1200/JCO.2016.69.7391

    Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors (Journal article)

    Vargas, F. A., Furness, A. J. S., Solomon, I., Joshi, K., Mekkaoui, L., Lesko, M. H., . . . Consortium, L. T. (2017). Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. IMMUNITY, 46(4), 577-586. doi:10.1016/j.immuni.2017.03.013

    DOI: 10.1016/j.immuni.2017.03.013

    Percutaneous Hepatic Perfusion (PHP) for Unresectable Metastatic Ocular Melanoma to the Liver: A Multi-Institutional Report of Outcomes (Conference Paper)

    Gangi, A., Karydis, I., Thomas, K., Sileno, S., Hardman, D., Choi, J., . . . Zager, J. S. (2017). Percutaneous Hepatic Perfusion (PHP) for Unresectable Metastatic Ocular Melanoma to the Liver: A Multi-Institutional Report of Outcomes. In ANNALS OF SURGICAL ONCOLOGY Vol. 24 (pp. S147). Retrieved from http://gateway.webofknowledge.com/

    Cancer Vaccines Preface (Chapter)

    Savelyeva, N., & Ottensmeier, C. (2017). Cancer Vaccines Preface. In CANCER VACCINES (Vol. 405, pp. V-VI). Retrieved from http://gateway.webofknowledge.com/

    Linked CD4 T Cell Help: Broadening Immune Attack Against Cancer by Vaccination (Journal article)

    Savelyeva, N., Allen, A., Chotprakaikiat, W., Harden, E., Jobsri, J., Godeseth, R., . . . Ottensmeier, C. (2017). Linked CD4 T Cell Help: Broadening Immune Attack Against Cancer by Vaccination. CANCER VACCINES, 405, 123-143. doi:10.1007/82_2016_500

    DOI: 10.1007/82_2016_500

    Novel Approaches for Vaccination Against HPV-Induced Cancers (Journal article)

    King, E., Ottensmeier, C., & Pollock, K. G. J. (2017). Novel Approaches for Vaccination Against HPV-Induced Cancers. CANCER VACCINES, 405, 33-53. doi:10.1007/82_2015_430

    DOI: 10.1007/82_2015_430

    2016

    Induction of fibroblast senescence generates a non-fibrogenic myofibroblast phenotype that differentially impacts on cancer prognosis (Journal article)

    Mellone, M., Hanley, C. J., Thirdborough, S., Mellows, T., Garcia, E., Woo, J., . . . Thomas, G. J. (2017). Induction of fibroblast senescence generates a non-fibrogenic myofibroblast phenotype that differentially impacts on cancer prognosis. AGING-US, 9(1), 128-146. doi:10.18632/aging.101127

    DOI: 10.18632/aging.101127

    Human Papillomavirus Drives Tumor Development Throughout the Head and Neck: Improved Prognosis Is Associated With an Immune Response Largely Restricted to the Oropharynx (Journal article)

    Chakravarthy, A., Henderson, S., Thirdborough, S. M., Ottensmeier, C. H., Su, X., Lechner, M., . . . Fenton, T. R. (2016). Human Papillomavirus Drives Tumor Development Throughout the Head and Neck: Improved Prognosis Is Associated With an Immune Response Largely Restricted to the Oropharynx. JOURNAL OF CLINICAL ONCOLOGY, 34(34), 4132-+. doi:10.1200/JCO.2016.68.2955

    DOI: 10.1200/JCO.2016.68.2955

    Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes (Journal article)

    McCann, K. J., Mander, A., Cazaly, A., Chudley, L., Stasakova, J., Thirdborough, S. M., . . . Ottensmeier, C. H. (2016). Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes. CLINICAL CANCER RESEARCH, 22(19), 4827-4836. doi:10.1158/1078-0432.CCR-15-2507

    DOI: 10.1158/1078-0432.CCR-15-2507

    Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis (Journal article)

    Arriola, E., Wheater, M., Lopez, M. A., Thomas, G., & Ottensmeier, C. (2016). Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis. ONCOIMMUNOLOGY, 5(9). doi:10.1080/2162402X.2016.1209615

    DOI: 10.1080/2162402X.2016.1209615

    LSC Abstract - Transcriptomic profiling of macrophages isolated from human non-small cell lung carcinoma (NSCLC) reveals novel macrophage subsets with distinct tumour response features (Conference Paper)

    Garrido-Martin, E. M., Martinez-Nunez, R., Mellows, T., Ottensmeier, C. H., Vijayanand, P., & Sanchez-Elsner, T. (2016). LSC Abstract - Transcriptomic profiling of macrophages isolated from human non-small cell lung carcinoma (NSCLC) reveals novel macrophage subsets with distinct tumour response features. In EUROPEAN RESPIRATORY JOURNAL Vol. 48. doi:10.1183/13993003.congress-2016.YI2

    DOI: 10.1183/13993003.congress-2016.YI2

    LSC Abstract - Transcriptomic profiling of macrophages isolated from human non-small cell lung carcinoma (NSCLC) reveals novel macrophage subsets with distinct tumour response features (Conference Paper)

    Garrido-Martin, E. M., Martinez-Nunez, R., Mellows, T., Ottensmeier, C. H., Vijayanand, P., & Sanchez-Elsner, T. (2016). LSC Abstract - Transcriptomic profiling of macrophages isolated from human non-small cell lung carcinoma (NSCLC) reveals novel macrophage subsets with distinct tumour response features. In EUROPEAN RESPIRATORY JOURNAL Vol. 48. doi:10.1183/13993003.congress-2016.OA1771

    DOI: 10.1183/13993003.congress-2016.OA1771

    Patterns of clinical response in talimogene laherparepvec (T-VEC) treated patients with stage IIIB-IVM1a melanoma in the OPTiM phase III trial (Conference Paper)

    Harrington, K., Kaufman, H., Middleton, M., Melcher, A., Ottensmeier, C., Safaei, R., . . . Andtbacka, R. H. I. (2016). Patterns of clinical response in talimogene laherparepvec (T-VEC) treated patients with stage IIIB-IVM1a melanoma in the OPTiM phase III trial. In MELANOMA RESEARCH Vol. 26 (pp. E4-E5). Retrieved from http://gateway.webofknowledge.com/

    Timing of onset and resolution of adverse events in patients with unresectable stage IIIB-IVM1a melanoma treated with talimogene laherparepvec (T-VEC) in OPTiM (Conference Paper)

    Andtbacka, R., Kaufman, H., Harrington, K., Middleton, M., Melcher, A., Ottensmeier, C., . . . Collichio, F. (2016). Timing of onset and resolution of adverse events in patients with unresectable stage IIIB-IVM1a melanoma treated with talimogene laherparepvec (T-VEC) in OPTiM. In MELANOMA RESEARCH Vol. 26 (pp. E36-E37). Retrieved from http://gateway.webofknowledge.com/

    Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors (Journal article)

    Wood, O., Woo, J., Seumois, G., Savelyeva, N., McCann, K. J., Singh, D., . . . Consortium, S. P. A. R. C. (2016). Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors. Oncotarget, 7(35), 56781-56797. doi:10.18632/oncotarget.10788

    DOI: 10.18632/oncotarget.10788

    GAPVAC-101 phase I trial: First data of an innovative actively personalized peptide vaccination trial in patients with newly diagnosed glioblastoma (Conference Paper)

    Hilf, N., Frenzel, K., Kuttruff-Coqui, S., Heesch, S., Kreiter, S., Admon, A., . . . Singh-Jasuja, H. (2016). GAPVAC-101 phase I trial: First data of an innovative actively personalized peptide vaccination trial in patients with newly diagnosed glioblastoma. In CANCER RESEARCH Vol. 76. doi:10.1158/1538-7445.AM2016-2654

    DOI: 10.1158/1538-7445.AM2016-2654

    Upregulated Glucose Metabolism Correlates Inversely with CD8(+) T-cell Infiltration and Survival in Squamous Cell Carcinoma (Journal article)

    Ottensmeier, C. H., Perry, K. L., Harden, E. L., Stasakova, J., Jenei, V., Fleming, J., . . . Thirdborough, S. M. (2016). Upregulated Glucose Metabolism Correlates Inversely with CD8(+) T-cell Infiltration and Survival in Squamous Cell Carcinoma. Cancer Research, 76(14), 4136-4148. doi:10.1158/0008-5472.CAN-15-3121

    DOI: 10.1158/0008-5472.CAN-15-3121

    A plant-expressed conjugate vaccine breaks CD4(+) tolerance and induces potent immunity against metastatic Her2(+) breast cancer (Journal article)

    Chotprakaikiat, W., Allen, A., Bui-Minh, D., Harden, E., Jobsri, J., Cavallo, F., . . . Savelyeva, N. (2016). A plant-expressed conjugate vaccine breaks CD4(+) tolerance and induces potent immunity against metastatic Her2(+) breast cancer. ONCOIMMUNOLOGY, 5(6). doi:10.1080/2162402X.2016.1166323

    DOI: 10.1080/2162402X.2016.1166323

    Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma (Journal article)

    Noble, F., Mellows, T., Matthews, L. H. M., Bateman, A. C., Harris, S., Underwood, T. J., . . . Ottensmeier, C. H. (2016). Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma. CANCER IMMUNOLOGY IMMUNOTHERAPY, 65(6), 651-662. doi:10.1007/s00262-016-1826-5

    DOI: 10.1007/s00262-016-1826-5

    UK experience of combined BRAF and MEK inhibition with dabrafenib and trametinib (D+1) in the metastatic melanoma (MM) named patient programme. (Conference Paper)

    Ellis, S. G., Pallan, L., Hategan, M., Price, N., Arkenau, H. -T., Steven, N., . . . Wheater, M. J. (2016). UK experience of combined BRAF and MEK inhibition with dabrafenib and trametinib (D+1) in the metastatic melanoma (MM) named patient programme.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34. doi:10.1200/JCO.2016.34.15_suppl.e21027

    DOI: 10.1200/JCO.2016.34.15_suppl.e21027

    UKMCC-01: A phase II study of pazopanib (PAZ) in metastatic Merkel cell carcinoma. (Conference Paper)

    Nathan, P. D., Gaunt, P., Wheatley, K., Bowden, S. J., Savage, J., Faust, G., . . . Steven, N. M. (2016). UKMCC-01: A phase II study of pazopanib (PAZ) in metastatic Merkel cell carcinoma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34. doi:10.1200/JCO.2016.34.15_suppl.9542

    DOI: 10.1200/JCO.2016.34.15_suppl.9542

    Mucosal-Associated Invariant T (MAIT) Cells Are Impaired in Th17 Associated Primary and Secondary Immunodeficiencies (Journal article)

    Gao, Y., Rae, W., Ramakrishnan, K. A., Barcenas-Morales, G., Doffinger, R., Eren, E., . . . Williams, A. P. (2016). Mucosal-Associated Invariant T (MAIT) Cells Are Impaired in Th17 Associated Primary and Secondary Immunodeficiencies. PLOS ONE, 11(5). doi:10.1371/journal.pone.0155059

    DOI: 10.1371/journal.pone.0155059

    Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma (Journal article)

    Karydis, I., Chan, P. Y., Wheater, M., Arriola, E., Szlosarek, P. W., & Ottensmeier, C. H. (2016). Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma. ONCOIMMUNOLOGY, 5(5). doi:10.1080/2162402X.2016.1143997

    DOI: 10.1080/2162402X.2016.1143997

    TG4010: a vaccine with a therapeutic role in cancer (Journal article)

    Arriola, E., & Ottensmeier, C. (2016). TG4010: a vaccine with a therapeutic role in cancer. IMMUNOTHERAPY, 8(5), 511-519. doi:10.2217/imt-2016-0015

    DOI: 10.2217/imt-2016-0015

    Wilms’ tumour antigen 1 Immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation: a Phase II non-randomised clinical trial (WIN) (Journal article)

    Ottensmeier, C., Bowers, M., Hamid, D., Maishman, T., Regan, S., Wood, W., . . . Stanton, L. (2016). Wilms’ tumour antigen 1 Immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation: a Phase II non-randomised clinical trial (WIN).

    Pharmacodynamic biomarkers for first in class early phase immuno-oncology trials; opportunities and challenges (Conference Paper)

    Katugampola, S., Spicer, J., Karagianis, S., Joseph, D., Bax, H., Pellizzari, G., . . . Jones, P. (2016). Pharmacodynamic biomarkers for first in class early phase immuno-oncology trials; opportunities and challenges. In EUROPEAN JOURNAL OF CANCER Vol. 55 (pp. S27). Retrieved from http://gateway.webofknowledge.com/

    TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial (Journal article)

    Quoix, E., Lena, H., Losonczy, G., Forget, F., Chouaid, C., Papai, Z., . . . Limacher, J. -M. (2016). TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. The Lancet Oncology, 17(2), 212-223. doi:10.1016/S1470-2045(15)00483-0

    DOI: 10.1016/S1470-2045(15)00483-0

    Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study (Journal article)

    Mandruzzato, S., Brandau, S., Britten, C. M., Bronte, V., Damuzzo, V., Gouttefangeas, C., . . . Walter, S. (2016). Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. CANCER IMMUNOLOGY IMMUNOTHERAPY, 65(2), 161-169. doi:10.1007/s00262-015-1782-5

    DOI: 10.1007/s00262-015-1782-5

    Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC (Journal article)

    Arriola, E., Wheater, M., Galea, I., Cross, N., Maishman, T., Hamid, D., . . . Ottensmeier, C. (2016). Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. JOURNAL OF THORACIC ONCOLOGY, 11(9), 1511-1521. doi:10.1016/j.jtho.2016.05.028

    DOI: 10.1016/j.jtho.2016.05.028

    The prognostic value of tumour infiltrating lymphocytes in cancer (Journal article)

    Mirza, A. H., Ottensmeier, C. H., Thomas, G. J., & King, E. V. (2016). The prognostic value of tumour infiltrating lymphocytes in cancer. Current Trends in Immunology, 17, 27-36.

    2015

    Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma (vol 113, pg 107, 2015) (Journal article)

    Matthews, L. H. M., Noble, F., Tod, J., Jaynes, E., Harris, S., Primrose, J. N., . . . Underwood, T. J. (2015). Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma (vol 113, pg 107, 2015). BRITISH JOURNAL OF CANCER, 113(12), 1746. doi:10.1038/bjc.2015.460

    DOI: 10.1038/bjc.2015.460

    Infliximab for IPILIMUMAB-Related Colitis-Letter (Journal article)

    Arriola, E., Wheater, M., Karydis, I., Thomas, G., & Ottensmeier, C. (2015). Infliximab for IPILIMUMAB-Related Colitis-Letter. CLINICAL CANCER RESEARCH, 21(24), 5642-5643. doi:10.1158/1078-0432.CCR-15-2471

    DOI: 10.1158/1078-0432.CCR-15-2471

    Uveal Melanoma UK National Guidelines (Journal article)

    Nathan, P., Cohen, V., Coupland, S., Curtis, K., Damato, B., Evans, J., . . . Turnbull, N. (2015). Uveal Melanoma UK National Guidelines. EUROPEAN JOURNAL OF CANCER, 51(16), 2404-2412. doi:10.1016/j.ejca.2015.07.013

    DOI: 10.1016/j.ejca.2015.07.013

    Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control (Journal article)

    Arriola, E., Wheater, M., Krishnan, R., Smart, J., Foria, V., & Ottensmeier, C. (2015). Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control. ONCOIMMUNOLOGY, 4(10). doi:10.1080/2162402X.2015.1040218

    DOI: 10.1080/2162402X.2015.1040218

    Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients (Journal article)

    Ahmad, S. S., Qian, W., Ellis, S., Mason, E., Khattak, M. A., Gupta, A., . . . Corrie, P. G. (2015). Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients. MELANOMA RESEARCH, 25(5), 432-442. doi:10.1097/CMR.0000000000000185

    DOI: 10.1097/CMR.0000000000000185

    Vaccination Expands Antigen-Specific CD4(+) Memory T Cells and Mobilizes Bystander Central Memory T Cells (Journal article)

    Li Causi, E., Parikh, S. C., Chudley, L., Layfield, D. M., Ottensmeier, C. H., Stevenson, F. K., & Di Genova, G. (2015). Vaccination Expands Antigen-Specific CD4(+) Memory T Cells and Mobilizes Bystander Central Memory T Cells. PLOS ONE, 10(9). doi:10.1371/journal.pone.0136717

    DOI: 10.1371/journal.pone.0136717

    Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse (Conference Paper)

    Clark, L., Hepburne-Scott, H., Ottensmeier, C., Middleton, M., Myers, K. A., Tarlton, A., . . . Nathan, P. (2015). Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse. In EUROPEAN JOURNAL OF CANCER Vol. 51 (pp. S686). doi:10.1016/S0959-8049(16)31871-8

    DOI: 10.1016/S0959-8049(16)31871-8

    TG4010 Immunotherapy plus Chemotherapy as First Line Treatment of Advanced NSCLC: Phase 2b Results (Conference Paper)

    Quoix, E., Forget, F., Chouaid, C., Papai, Z., Losonczy, G., Felip, E., . . . Lena, H. (2015). TG4010 Immunotherapy plus Chemotherapy as First Line Treatment of Advanced NSCLC: Phase 2b Results. In JOURNAL OF THORACIC ONCOLOGY Vol. 10 (pp. S208). Retrieved from http://gateway.webofknowledge.com/

    Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study (Journal article)

    McCann, K. J., Godeseth, R., Chudley, L., Mander, A., Di Genova, G., Lloyd-Evans, P., . . . Ottensmeier, C. H. (2015). Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study. CANCER IMMUNOLOGY IMMUNOTHERAPY, 64(8), 1021-1032. doi:10.1007/s00262-015-1703-7

    DOI: 10.1007/s00262-015-1703-7

    Staging and treatment of oropharyngeal cancer in the human papillomavirus era (Journal article)

    Ward, M. J., Mellows, T., Harris, S., Webb, A., Patel, N. N., Cox, H. J., . . . King, E. V. (2015). Staging and treatment of oropharyngeal cancer in the human papillomavirus era. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 37(7), 1002-1013. doi:10.1002/hed.23697

    DOI: 10.1002/hed.23697

    Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma (Journal article)

    Matthews, L. H. M., Noble, F., Tod, J., Jaynes, E., Harris, S., Primrose, J. N., . . . Underwood, T. J. (2015). Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma. BRITISH JOURNAL OF CANCER, 113(1), 107-118. doi:10.1038/bjc.2015.179

    DOI: 10.1038/bjc.2015.179

    An adjuvant clinical trial of SCIB1, a DNA vaccine that targets dendritic cells in vivo, in fully resected melanoma patients (Conference Paper)

    Patel, P. M., Ottensmeier, C., Mulatero, C., Lorigan, P., Plummer, R., Hannaman, D., . . . Durrant, L. G. (2015). An adjuvant clinical trial of SCIB1, a DNA vaccine that targets dendritic cells in vivo, in fully resected melanoma patients. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33. Retrieved from http://gateway.webofknowledge.com/

    Evaluation of the impact of infliximab use for the treatment of ipilimumab related diarrhoea on the outcome of patients with advanced melanoma. (Conference Paper)

    Arriola, E., Wheater, M. J., Warrier, A., Karydis, I., & Ottensmeier, C. H. H. (2015). Evaluation of the impact of infliximab use for the treatment of ipilimumab related diarrhoea on the outcome of patients with advanced melanoma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33. Retrieved from http://gateway.webofknowledge.com/

    Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy. (Conference Paper)

    Quoix, E. A., Forget, F., Papai-Szekely, Z., Ottensmeier, C. H. H., Nemunaitis, J. J., Felip, E., . . . Limacher, J. -M. (2015). Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33. doi:10.1200/jco.2015.33.15_suppl.3034

    DOI: 10.1200/jco.2015.33.15_suppl.3034

    Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse. (Conference Paper)

    Clark, L. L., Hepburne-Scott, H., Middleton, M. R., Ottensmeier, C. H. H., Myers, K. A., Tarlton, A. B., . . . Nathan, P. D. (2015). Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33. Retrieved from http://gateway.webofknowledge.com/

    Single centre experience of chemosaturation percutaneous hepatic perfusion in the treatment of metastatic uveal melanoma. (Conference Paper)

    Hickson, G., Karydis, I., Wheater, M. J., Takar, A., Wilson, I., Pearce, N., . . . Stedman, B. (2015). Single centre experience of chemosaturation percutaneous hepatic perfusion in the treatment of metastatic uveal melanoma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33. Retrieved from http://gateway.webofknowledge.com/

    The association of T cells with survival in mesothelioma. (Conference Paper)

    Chee, S. J., Lopez, M., Mellows, T., Alzetani, A., Thomas, G., & Ottensmeier, C. H. H. (2015). The association of T cells with survival in mesothelioma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33. Retrieved from http://gateway.webofknowledge.com/

    Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters (Journal article)

    Gouttefangeas, C., Chan, C., Attig, S., Kollgaard, T. T., Rammensee, H. -G., Stevanovic, S., . . . Britten, C. M. (2015). Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters. CANCER IMMUNOLOGY IMMUNOTHERAPY, 64(5), 585-598. doi:10.1007/s00262-014-1649-1

    DOI: 10.1007/s00262-014-1649-1

    Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study (Journal article)

    Johnson, P., Challis, R., Chowdhury, F., Gao, Y., Harvey, M., Geldart, T., . . . Williams, A. (2015). Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study. CLINICAL CANCER RESEARCH, 21(6), 1321-1328. doi:10.1158/1078-0432.CCR-14-2355

    DOI: 10.1158/1078-0432.CCR-14-2355

    NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus (Journal article)

    Chen, J. -L., Dawoodji, A., Tarlton, A., Gnjatic, S., Tajar, A., Karydis, I., . . . Cerundolo, V. (2015). NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus. INTERNATIONAL JOURNAL OF CANCER, 136(6), E590-E601. doi:10.1002/ijc.29118

    DOI: 10.1002/ijc.29118

    Plant Virus Particles Carrying Tumour Antigen Activate TLR7 and Induce High Levels of Protective Antibody (Journal article)

    Jobsri, J., Allen, A., Rajagopal, D., Shipton, M., Kanyuka, K., Lomonossoff, G. P., . . . Savelyeva, N. (2015). Plant Virus Particles Carrying Tumour Antigen Activate TLR7 and Induce High Levels of Protective Antibody. PLOS ONE, 10(2). doi:10.1371/journal.pone.0118096

    DOI: 10.1371/journal.pone.0118096

    Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future (Chapter)

    Gouttefangeas, C., Walter, S., Welters, M. J. P., Ottensmeier, C., van der Burg, S. H., Britten, C. M., & Chan, C. (2015). Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future. In Cancer Immunology (pp. 471-490). Springer Berlin Heidelberg. doi:10.1007/978-3-662-44006-3_25

    DOI: 10.1007/978-3-662-44006-3_25

    TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced non small cell lung cancer (NSCLC): Phase IIb results of the TIME trial (Journal article)

    Nemunaitis, J., Papai, Z., Léna, H., Losonczy, G., Forget, F., Chouaid, C., . . . Quoix, E. (2015). TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced non small cell lung cancer (NSCLC): Phase IIb results of the TIME trial. Journal for immunotherapy of cancer, 3(Suppl 2), P441. doi:10.1186/2051-1426-3-s2-p441

    DOI: 10.1186/2051-1426-3-s2-p441

    2014

    Tumour Infiltrating Lymphocytes Associate with Improved Survival in Oesophageal Adenocarcinoma (Conference Paper)

    Noble, F., Mellows, T., Matthews, L. M., Bateman, A., Byrne, J., Bailey, I., . . . Ottensmeier, C. (2014). Tumour Infiltrating Lymphocytes Associate with Improved Survival in Oesophageal Adenocarcinoma. In BRITISH JOURNAL OF SURGERY Vol. 101 (pp. 36). Retrieved from http://gateway.webofknowledge.com/

    TIME, a Phase 2b/3 Study Evaluating TG4010 in Combination With First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 2b Results (Conference Paper)

    Quoix, E., Losonczy, G., Forget, F., Chouaid, C., Papai, Z., Gervais, R., . . . Lena, H. (2014). TIME, a Phase 2b/3 Study Evaluating TG4010 in Combination With First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 2b Results. In INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS Vol. 90 (pp. S35). doi:10.1016/j.ijrobp.2014.08.211

    DOI: 10.1016/j.ijrobp.2014.08.211

    Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining (Journal article)

    Chudley, L., McCann, K. J., Coleman, A., Cazaly, A. M., Bidmon, N., Britten, C. M., . . . Ottensmeier, C. H. (2014). Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining. CANCER IMMUNOLOGY IMMUNOTHERAPY, 63(11), 1199-1211. doi:10.1007/s00262-014-1593-0

    DOI: 10.1007/s00262-014-1593-0

    Mucosal-Associated Invariant T Cells in Primary and Secondary Immunodeficiency Patients (Conference Paper)

    Gao, Y., Ramakrishnan, K. A., Barcenas-Morales, G., Doeffinger, R., Pengelly, R., Ennis, S., . . . Williams, A. (2014). Mucosal-Associated Invariant T Cells in Primary and Secondary Immunodeficiency Patients. In JOURNAL OF CLINICAL IMMUNOLOGY Vol. 34 (pp. S497-S498). Retrieved from http://gateway.webofknowledge.com/

    Phase I/II trial of a novel antibody DNA immunotherapy, targeting CD64, in the treatment of Melanoma (Conference Paper)

    Durrant, L. G., Ottensmeier, C. H., Lorigan, P., Mulatero, C., Plummer, R., Cunell, M., . . . Patel, P. (2014). Phase I/II trial of a novel antibody DNA immunotherapy, targeting CD64, in the treatment of Melanoma. In CANCER RESEARCH Vol. 74. doi:10.1158/1538-7445.AM2014-CT331

    DOI: 10.1158/1538-7445.AM2014-CT331

    Anti-CTLA-4 therapy broadens the melanoma-reactive CD8(+) T cell response (Journal article)

    Kvistborg, P., Philips, D., Kelderman, S., Hageman, L., Ottensmeier, C., Joseph-Pietras, D., . . . Schumacher, T. N. (2014). Anti-CTLA-4 therapy broadens the melanoma-reactive CD8(+) T cell response. SCIENCE TRANSLATIONAL MEDICINE, 6(254). doi:10.1126/scitranslmed.3008918

    DOI: 10.1126/scitranslmed.3008918

    A NOVEL PHASE II TRIAL OF IPILIMUMAB, CARBOPLATIN AND ETOPOSIDE (ICE) FOR THE FIRST LINE TREATMENT OF EXTENSIVE STAGE SMALL CELL LUNG CANCER (SCLC) (Conference Paper)

    Ottensmeier, C., Galea, I., Cross, N., Maishman, T., Hamid, D., Cave, J., . . . Nolan, L. (2014). A NOVEL PHASE II TRIAL OF IPILIMUMAB, CARBOPLATIN AND ETOPOSIDE (ICE) FOR THE FIRST LINE TREATMENT OF EXTENSIVE STAGE SMALL CELL LUNG CANCER (SCLC). In ANNALS OF ONCOLOGY Vol. 25. doi:10.1093/annonc/mdu355.15

    DOI: 10.1093/annonc/mdu355.15

    Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases (Journal article)

    Lee, S. M., Lewanski, C. R., Counsell, N., Ottensmeier, C., Bates, A., Patel, N., . . . Faivre-Finn, C. (2014). Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 106(7). doi:10.1093/jnci/dju151

    DOI: 10.1093/jnci/dju151

    Phase I trial of ImmunoBody in melanoma patients. (Conference Paper)

    Patel, P. M., Durrant, L. G., Ottensmeier, C., Mulatero, C., Lorigan, P., Plummer, R., . . . Hannaman, D. (2014). Phase I trial of ImmunoBody in melanoma patients.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32. doi:10.1200/jco.2014.32.15_suppl.3061

    DOI: 10.1200/jco.2014.32.15_suppl.3061

    Randomized, double-blind phase II trial of NY-ESO-1 ISCOMATRIX vaccine and ISCOMATRIX adjuvant alone in patients with resected stage IIc, III, or IV malignant melanoma. (Conference Paper)

    Cebon, J. S., McArthur, G. A., Chen, W., Davis, I. D., Gore, M. E., Thompson, J. F., . . . Evans, T. R. J. (2014). Randomized, double-blind phase II trial of NY-ESO-1 ISCOMATRIX vaccine and ISCOMATRIX adjuvant alone in patients with resected stage IIc, III, or IV malignant melanoma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32. doi:10.1200/jco.2014.32.15_suppl.9050

    DOI: 10.1200/jco.2014.32.15_suppl.9050

    DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma (Journal article)

    Gupta, A., Love, S., Schuh, A., Shanyinde, M., Larkin, J. M., Plummer, R., . . . Middleton, M. R. (2014). DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. ANNALS OF ONCOLOGY, 25(5), 968-974. doi:10.1093/annonc/mdu054

    DOI: 10.1093/annonc/mdu054

    A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors (Journal article)

    Angevin, E., Tabernero, J., Elez, E., Cohen, S. J., Bahleda, R., van Laethem, J. -L., . . . Kurzrock, R. (2014). A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors. CLINICAL CANCER RESEARCH, 20(8), 2192-2204. doi:10.1158/1078-0432.CCR-13-2200

    DOI: 10.1158/1078-0432.CCR-13-2200

    Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer (Journal article)

    Ward, M. J., Thirdborough, S. M., Mellows, T., Riley, C., Harris, S., Suchak, K., . . . Thomas, G. J. (2014). Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. BRITISH JOURNAL OF CANCER, 110(2), 489-500. doi:10.1038/bjc.2013.639

    DOI: 10.1038/bjc.2013.639

    Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme (Journal article)

    Khan, F., Ottensmeier, C., Popat, S., Dua, D., Dorey, N., Ellis, S., . . . Danson, S. J. (2014). Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme. EUROPEAN JOURNAL OF CANCER, 50(10), 1717-1721. doi:10.1016/j.ejca.2014.03.001

    DOI: 10.1016/j.ejca.2014.03.001

    Suppression of Hedgehog signalling promotes pro-tumourigenic integrin expression and function (Journal article)

    Moutasim, K. A., Mellows, T., Mellone, M., Lopez, M. -A., Tod, J., Kiely, P. C., . . . Thomas, G. J. (2014). Suppression of Hedgehog signalling promotes pro-tumourigenic integrin expression and function. JOURNAL OF PATHOLOGY, 233(2), 196-208. doi:10.1002/path.4342

    DOI: 10.1002/path.4342

    Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial (Journal article)

    Butts, C., Socinski, M. A., Mitchell, P. L., Thatcher, N., Havel, L., Krzakowski, M., . . . Team, S. T. A. R. T. T. (2014). Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. LANCET ONCOLOGY, 15(1), 59-68. doi:10.1016/S1470-2045(13)70510-2

    DOI: 10.1016/S1470-2045(13)70510-2

    The effect of neoadjuvant chemotherapy on physical fitness and survival in patients undergoing oesophagogastric cancer surgery (Journal article)

    Jack, S., West, M. A., Raw, D., Marwood, S., Ambler, G., Cope, T. M., . . . Grocott, M. P. W. (2014). The effect of neoadjuvant chemotherapy on physical fitness and survival in patients undergoing oesophagogastric cancer surgery. EJSO, 40(10), 1313-1320. doi:10.1016/j.ejso.2014.03.010

    DOI: 10.1016/j.ejso.2014.03.010

    The immune response in HPV+ oropharyngeal cancer (Journal article)

    King, E. V., Ottensmeier, C. H., & Thomas, G. J. (2014). The immune response in HPV+ oropharyngeal cancer. ONCOIMMUNOLOGY, 3(1). doi:10.4161/onci.27254

    DOI: 10.4161/onci.27254

    The role of the reporting framework MIATA within current efforts to advance immune monitoring (Journal article)

    Janetzki, S., Britten, C. M., Davis, M. M., Hoos, A., Huber, C., Kalos, M., . . . Team, M. I. A. T. A. C. (2014). The role of the reporting framework MIATA within current efforts to advance immune monitoring. JOURNAL OF IMMUNOLOGICAL METHODS, 409, 6-8. doi:10.1016/j.jim.2014.05.003

    DOI: 10.1016/j.jim.2014.05.003

    Treatment and outcome in epidermal growth factor receptor mutant non-small cell lung cancer: A retrospective audit across four NHS trusts (Conference Paper)

    Killick, E., Bennett, J., Bates, A., Bhatnagar, A., Fenton, P., Ottensmeier, C., . . . Nolan, L. (2014). Treatment and outcome in epidermal growth factor receptor mutant non-small cell lung cancer: A retrospective audit across four NHS trusts. In LUNG CANCER Vol. 83 (pp. S10-S11). doi:10.1016/S0169-5002(14)70027-3

    DOI: 10.1016/S0169-5002(14)70027-3

    2013

    A MULTICENTER PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF PRAVASTATIN ADDED TO FIRST-LINE STANDARD CHEMOTHERAPY IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC) (Conference Paper)

    Seckl, M. J., Ottensmeier, C., Cullen, M., Schmid, P., James, L., Wadsworth, C., . . . Khan, I. (2013). A MULTICENTER PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF PRAVASTATIN ADDED TO FIRST-LINE STANDARD CHEMOTHERAPY IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC). In JOURNAL OF THORACIC ONCOLOGY Vol. 8 (pp. S219). Retrieved from http://gateway.webofknowledge.com/

    A RANDOMISED PLACEBO-CONTROLLED MULTICENTRE PHASE II TRIAL OF ERLOTINIB PLUS WHOLE BRAIN RADIOTHERAPY FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WITH MULTIPLE BRAIN METASTASES (TACTIC) (Conference Paper)

    Lee, S. M., Lewanski, C., Counsell, N., Ottensmeier, C., Bates, A. T., Patel, N., . . . Faivre-Finn, C. (2013). A RANDOMISED PLACEBO-CONTROLLED MULTICENTRE PHASE II TRIAL OF ERLOTINIB PLUS WHOLE BRAIN RADIOTHERAPY FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WITH MULTIPLE BRAIN METASTASES (TACTIC). In JOURNAL OF THORACIC ONCOLOGY Vol. 8 (pp. S298-S299). Retrieved from http://gateway.webofknowledge.com/

    Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial) (Journal article)

    Ramalingam, S., Crawford, J., Chang, A., Manegold, C., Perez-Soler, R., Douillard, J. -Y., . . . Investigators, F. O. R. T. I. S. -M. S. (2013). Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). ANNALS OF ONCOLOGY, 24(11), 2875-2880. doi:10.1093/annonc/mdt371

    DOI: 10.1093/annonc/mdt371

    Tumour infiltrating lymphocytes levels within colorectal liver metastases correlate with oncological outcomes (Conference Paper)

    Curtis, N., Primrose, J. N., Mirnezami, A. H., Thomas, G. J., Bruce, A., Pugh, S., & Ottensmeier, C. H. (2013). Tumour infiltrating lymphocytes levels within colorectal liver metastases correlate with oncological outcomes. In EUROPEAN JOURNAL OF CANCER Vol. 49 (pp. S564). Retrieved from http://gateway.webofknowledge.com/

    FOXO3 expression during colorectal cancer progression: biomarker potential reflects a tumour suppressor role (Journal article)

    Bullock, M. D., Bruce, A., Sreekumar, R., Curtis, N., Cheung, T., Reading, I., . . . Mirnezami, A. H. (2013). FOXO3 expression during colorectal cancer progression: biomarker potential reflects a tumour suppressor role. BRITISH JOURNAL OF CANCER, 109(2), 387-394. doi:10.1038/bjc.2013.355

    DOI: 10.1038/bjc.2013.355

    DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma (Conference Paper)

    Gupta, A., Love, S., Schuh, A., Collins, L., Thomason, A., Asher, R., . . . Middleton, M. R. (2013). DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma. In JOURNAL OF CLINICAL ONCOLOGY Vol. 31. Retrieved from http://gateway.webofknowledge.com/

    Dissection of anti-CTLA4-induced cytotoxic T-cell responses in melanoma (Conference Paper)

    Haanen, J. B. A. G., Kvistborg, P., Philips, D., Kelderman, S., Heemskerk, B., Ottensmeier, C., . . . Schumacher, T. (2013). Dissection of anti-CTLA4-induced cytotoxic T-cell responses in melanoma. In JOURNAL OF CLINICAL ONCOLOGY Vol. 31. Retrieved from http://gateway.webofknowledge.com/

    Ipilimumab in the real world: The UK expanded access programme (EAP) experience in advanced melanoma. (Conference Paper)

    Ahmad, S., Qian, W., Ellis, S. G., Khattak, M. A., Gupta, A., Thillai, K., . . . Corrie, P. (2013). Ipilimumab in the real world: The UK expanded access programme (EAP) experience in advanced melanoma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 31. Retrieved from http://gateway.webofknowledge.com/

    Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma (Conference Paper)

    Sacco, J. J., Nathan, P. D., Danson, S., Lorigan, P., Nicholson, S., Ottensmeier, C., . . . Marshall, E. (2013). Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma. In JOURNAL OF CLINICAL ONCOLOGY Vol. 31. Retrieved from http://gateway.webofknowledge.com/

    A trial of agonistic anti-CD40 antibody: Biological effects in a Cancer Research UK phase I study. (Conference Paper)

    Johnson, P. W., Challis, R., Chowdhury, F., Chan, C., Smith, A., Steven, N., . . . Glennie, M. (2013). A trial of agonistic anti-CD40 antibody: Biological effects in a Cancer Research UK phase I study.. In CANCER RESEARCH Vol. 73. doi:10.1158/1538-7445.AM2013-LB-142

    DOI: 10.1158/1538-7445.AM2013-LB-142

    Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols (Journal article)

    Filbert, H., Attig, S., Bidmon, N., Renard, B. Y., Janetzki, S., Sahin, U., . . . Britten, C. M. (2013). Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols. CANCER IMMUNOLOGY IMMUNOTHERAPY, 62(4), 615-627. doi:10.1007/s00262-012-1359-5

    DOI: 10.1007/s00262-012-1359-5

    The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study (Journal article)

    Singh, S. K., Tummers, B., Schumacher, T. N., Gomez, R., Franken, K. L. M. C., Verdegaal, E. M., . . . van der Burg, S. H. (2013). The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study. CANCER IMMUNOLOGY IMMUNOTHERAPY, 62(3), 489-501. doi:10.1007/s00262-012-1351-0

    DOI: 10.1007/s00262-012-1351-0

    Afatanib use in non-small cell cancer patients whose tumours have been previously sensitive to EGFR inhibitors: the UK Named Patient Use experience (Conference Paper)

    Khan, F., Ottensmeier, C., Popat, S., & Danson, S. J. (2013). Afatanib use in non-small cell cancer patients whose tumours have been previously sensitive to EGFR inhibitors: the UK Named Patient Use experience. In LUNG CANCER Vol. 79 (pp. S10-S11). doi:10.1016/S0169-5002(13)70030-8

    DOI: 10.1016/S0169-5002(13)70030-8

    Genetic Vaccines against Cancer (Chapter)

    Stevenson, F. K., di Genova, G., Ottensmeier, C. H., & Savelyeva, N. (2013). Genetic Vaccines against Cancer. In Cancer Immunotherapy (pp. 223-239). Elsevier. doi:10.1016/b978-0-12-394296-8.00015-4

    DOI: 10.1016/b978-0-12-394296-8.00015-4

    Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052) (Journal article)

    O'Brien, M. E. R., Gaafar, R. M., Popat, S., Grossi, F., Price, A., Talbot, D. C., . . . Baas, P. (2013). Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). EUROPEAN JOURNAL OF CANCER, 49(13), 2815-2822. doi:10.1016/j.ejca.2013.05.008

    DOI: 10.1016/j.ejca.2013.05.008

    2012

    A Phase I Clinical Trial of Irinotecan and Carboplatin in Patients with Extensive Stage Small Cell Lung Cancer (Journal article)

    Crabb, S. J., Bradbury, J., Nolan, L., Selman, D., Muthuramalingam, S. R., Cave, J., . . . Ottensmeier, C. (2012). A Phase I Clinical Trial of Irinotecan and Carboplatin in Patients with Extensive Stage Small Cell Lung Cancer. CHEMOTHERAPY, 58(4), 257-263. doi:10.1159/000341274

    DOI: 10.1159/000341274

    DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time (Journal article)

    Chudley, L., McCann, K., Mander, A., Tjelle, T., Campos-Perez, J., Godeseth, R., . . . Ottensmeier, C. (2012). DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time. CANCER IMMUNOLOGY IMMUNOTHERAPY, 61(11), 2161-2170. doi:10.1007/s00262-012-1270-0

    DOI: 10.1007/s00262-012-1270-0

    Cancer classification using the Immunoscore: a worldwide task force (Journal article)

    Galon, J., Pages, F., Marincola, F. M., Angell, H. K., Thurin, M., Lugli, A., . . . Fox, B. A. (2012). Cancer classification using the Immunoscore: a worldwide task force. JOURNAL OF TRANSLATIONAL MEDICINE, 10. doi:10.1186/1479-5876-10-205

    DOI: 10.1186/1479-5876-10-205

    The Cancer Immunotherapy Immunoguiding Program (CIP): An international network for the harmonization of cellular immunological biomarkers (Conference Paper)

    Walter, S., Gouttefangeas, C., Britten, C. M., Ottensmeier, C. H., Welters, M. J. P., & van der Burg, S. H. (2012). The Cancer Immunotherapy Immunoguiding Program (CIP): An international network for the harmonization of cellular immunological biomarkers. In TUMOR BIOLOGY Vol. 33 (pp. 65). Retrieved from http://gateway.webofknowledge.com/

    The adaptive immune response to colorectal cancer: From the laboratory to clinical practice (Journal article)

    Curtis, N. J., Primrose, J. N., Thomas, G. J., Mirnezami, A. H., & Ottensmeier, C. H. (2012). The adaptive immune response to colorectal cancer: From the laboratory to clinical practice. EJSO, 38(10), 889-896. doi:10.1016/j.ejso.2012.05.011

    DOI: 10.1016/j.ejso.2012.05.011

    T Cell Assays and MIATA: The Essential Minimum for Maximum Impact (Journal article)

    Britten, C. M., Janetzki, S., Butterfield, L. H., Ferrari, G., Gouttefangeas, C., Huber, C., . . . Davis, M. M. (2012). T Cell Assays and MIATA: The Essential Minimum for Maximum Impact. IMMUNITY, 37(1), 1-2. doi:10.1016/j.immuni.2012.07.010

    DOI: 10.1016/j.immuni.2012.07.010

    Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma (Journal article)

    Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., . . . Grp, M. E. T. R. I. C. S. (2012). Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. NEW ENGLAND JOURNAL OF MEDICINE, 367(2), 107-114. doi:10.1056/NEJMoa1203421

    DOI: 10.1056/NEJMoa1203421

    Harmonization of the intracellular cytokine staining assay (Journal article)

    Welters, M. J. P., Gouttefangeas, C., Ramwadhdoebe, T. H., Letsch, A., Ottensmeier, C. H., Britten, C. M., & van der Burg, S. H. (2012). Harmonization of the intracellular cytokine staining assay. CANCER IMMUNOLOGY IMMUNOTHERAPY, 61(7), 967-978. doi:10.1007/s00262-012-1282-9

    DOI: 10.1007/s00262-012-1282-9

    Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment (Journal article)

    Revicki, D. A., van den Eertwegh, A. J. M., Lorigan, P., Lebbe, C., Linette, G., Ottensmeier, C. H., . . . Kotapati, S. (2012). Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. HEALTH AND QUALITY OF LIFE OUTCOMES, 10. doi:10.1186/1477-7525-10-66

    DOI: 10.1186/1477-7525-10-66

    A randomized phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma. (Conference Paper)

    Marshall, E., Coupland, S., Corrie, P., Damato, B., Danson, S., Dobson, L., . . . Nathan, P. D. (2012). A randomized phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30. Retrieved from http://gateway.webofknowledge.com/

    Biomarker for benefit from ipilimumab: Correlation of breadth of humoral tumor-antigen-specific immunity with outcome. (Conference Paper)

    Ellis, S. G., Wheater, M., Tier, K., Cazaly, A., Smart, J., Theaker, J., . . . Ottensmeier, C. H. H. (2012). Biomarker for benefit from ipilimumab: Correlation of breadth of humoral tumor-antigen-specific immunity with outcome.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30. Retrieved from http://gateway.webofknowledge.com/

    Phase I/II, two-part, open-label, multiple-dose, dose-escalation study of siltuximab in patients with solid tumors (Conference Paper)

    Angevin, E., Elez, E., Cohen, S. J., Van Laethem, J. -L., Ottensmeier, C., Joly, F., . . . Kurzrock, R. (2012). Phase I/II, two-part, open-label, multiple-dose, dose-escalation study of siltuximab in patients with solid tumors. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30. Retrieved from http://gateway.webofknowledge.com/

    Phase II study of bortezomib with cisplatin as first-line treatment of malignant pleural mesothelioma (MPM): EORTC 08052 (Conference Paper)

    O'Brien, M., Gaafar, R. M., Popat, S., Grossi, F., Price, A., Talbot, D. C., . . . Baas, P. (2012). Phase II study of bortezomib with cisplatin as first-line treatment of malignant pleural mesothelioma (MPM): EORTC 08052. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30. Retrieved from http://gateway.webofknowledge.com/

    CD8+T-cell cross-competition is governed by peptide-MHC class I stability (Journal article)

    Galea, I., Stasakova, J., Dunscombe, M. S., Ottensmeier, C. H., Elliott, T., & Thirdborough, S. M. (2012). CD8+T-cell cross-competition is governed by peptide-MHC class I stability. EUROPEAN JOURNAL OF IMMUNOLOGY, 42(1), 256-263. doi:10.1002/eji.201142010

    DOI: 10.1002/eji.201142010

    Dissection of Anti-CTLA4-induced Cytotoxic T Cell Responses in Melanoma (Conference Paper)

    Kvistborg, P., Philips, D., Kelderman, S., Hemskerk, B., Ottensmeier, C., Ribas, A., . . . Schumacher, T. (2012). Dissection of Anti-CTLA4-induced Cytotoxic T Cell Responses in Melanoma. In JOURNAL OF IMMUNOTHERAPY Vol. 35 (pp. 760-761). Retrieved from http://gateway.webofknowledge.com/

    Harmonization of Cellular Immunological Biomarkers by an International Network: The Cancer Immunotherapy Immunoguiding Program (CIP) (Conference Paper)

    Welters, M. J., Gouttefangeas, C., Ottensmeier, C. H., Walter, S., Britten, C. M., & van der Burg, S. H. (2012). Harmonization of Cellular Immunological Biomarkers by an International Network: The Cancer Immunotherapy Immunoguiding Program (CIP). In JOURNAL OF IMMUNOTHERAPY Vol. 35 (pp. 762). Retrieved from http://gateway.webofknowledge.com/

    2011

    Defining the critical hurdles in cancer immunotherapy (Journal article)

    Fox, B. A., Schendel, D. J., Butterfield, L. H., Aamdal, S., Allison, J. P., Ascierto, P. A., . . . Disis, M. L. (2011). Defining the critical hurdles in cancer immunotherapy. JOURNAL OF TRANSLATIONAL MEDICINE, 9. doi:10.1186/1479-5876-9-214

    DOI: 10.1186/1479-5876-9-214

    Harmonization of Immune Biomarker Assays for Clinical Studies (Journal article)

    van der Burg, S. H., Kalos, M., Gouttefangeas, C., Janetzki, S., Ottensmeier, C., Welters, M. J. P., . . . Hoos, A. (2011). Harmonization of Immune Biomarker Assays for Clinical Studies. SCIENCE TRANSLATIONAL MEDICINE, 3(108). doi:10.1126/scitranslmed.3002785

    DOI: 10.1126/scitranslmed.3002785

    DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen (Journal article)

    Vittes, G. E., Harden, E. L., Ottensmeier, C. H., Rice, J., & Stevenson, F. K. (2011). DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen. EUROPEAN JOURNAL OF IMMUNOLOGY, 41(8), 2447-2456. doi:10.1002/eji.201141518

    DOI: 10.1002/eji.201141518

    DNA fusion vaccines enter the clinic (Journal article)

    Stevenson, F. K., Mander, A., Chudley, L., & Ottensmeier, C. H. (2011). DNA fusion vaccines enter the clinic. CANCER IMMUNOLOGY IMMUNOTHERAPY, 60(8), 1147-1151. doi:10.1007/s00262-011-1042-2

    DOI: 10.1007/s00262-011-1042-2

    A randomised, phase II study of intetumumab, an anti-alpha(v)-integrin mAb, alone and with dacarbazine in stage IV melanoma (Journal article)

    O'Day, S., Pavlick, A., Loquai, C., Lawson, D., Gutzmer, R., Richards, J., . . . Investigators, C. N. T. O. . (2011). A randomised, phase II study of intetumumab, an anti-alpha(v)-integrin mAb, alone and with dacarbazine in stage IV melanoma. BRITISH JOURNAL OF CANCER, 105(3), 346-352. doi:10.1038/bjc.2011.183

    DOI: 10.1038/bjc.2011.183

    Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies (Journal article)

    Eisen, T., Marais, R., Affolter, A., Lorigan, P., Robert, C., Corrie, P., . . . Gore, M. E. (2011). Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. BRITISH JOURNAL OF CANCER, 105(3), 353-359. doi:10.1038/bjc.2011.257

    DOI: 10.1038/bjc.2011.257

    Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation (Journal article)

    Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., . . . Grp, B. S. (2011). Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. NEW ENGLAND JOURNAL OF MEDICINE, 364(26), 2507-2516. doi:10.1056/NEJMoa1103782

    DOI: 10.1056/NEJMoa1103782

    Phase I dose finding study of irinotecan in combination with carboplatin in treatment naive extensive stage small cell lung cancer (Conference Paper)

    Nolan, L., Bradbury, J. A., Muthuramalingam, S., Cave, J., Johnson, P. W. M., Ottensmeier, C. H., & Crabb, S. C. (2011). Phase I dose finding study of irinotecan in combination with carboplatin in treatment naive extensive stage small cell lung cancer. In LUNG CANCER Vol. 71 (pp. S41). doi:10.1016/S0169-5002(11)70119-2

    DOI: 10.1016/S0169-5002(11)70119-2

    2010

    A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles. (Journal article)

    Butler, M. O., Ansén, S., Tanaka, M., Imataki, O., Berezovskaya, A., Mooney, M. M., . . . Hirano, N. (2010). A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles.. International immunology, 22(11), 863-873. doi:10.1093/intimm/dxq440

    DOI: 10.1093/intimm/dxq440

    Ig gene diversification and selection in follicular lymphoma, diffuse large B cell lymphoma and primary central nervous system lymphoma revealed by lineage tree and mutation analyses (Journal article)

    Zuckerman, N. S., McCann, K. J., Ottensmeier, C. H., Barak, M., Shahaf, G., Edelman, H., . . . Mehr, R. (2010). Ig gene diversification and selection in follicular lymphoma, diffuse large B cell lymphoma and primary central nervous system lymphoma revealed by lineage tree and mutation analyses. INTERNATIONAL IMMUNOLOGY, 22(11), 875-887. doi:10.1093/intimm/dxq441

    DOI: 10.1093/intimm/dxq441

    Melanoma sentinel node biopsy and prediction models for relapse and overall survival (Journal article)

    Mitra, A., Conway, C., Walker, C., Cook, M., Powell, B., Lobo, S., . . . Newton-Bishop, J. A. (2010). Melanoma sentinel node biopsy and prediction models for relapse and overall survival. BRITISH JOURNAL OF CANCER, 103(8), 1229-1236. doi:10.1038/sj.bjc.6605849

    DOI: 10.1038/sj.bjc.6605849

    HEALTH RELATED QUALITY OF LIFE (HRQL) OUTCOMES OF IPILIMUMAB TREATMENT IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE STAGE III OR IV MELANOMA (USIII/IV MEL) (Conference Paper)

    Revicki, D., Kotapati, S., van Den Eertwegh, A. J., Lorigan, P., Linette, G., Ottensmeier, C. H., . . . Wagner, S. (2010). HEALTH RELATED QUALITY OF LIFE (HRQL) OUTCOMES OF IPILIMUMAB TREATMENT IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE STAGE III OR IV MELANOMA (USIII/IV MEL). In ANNALS OF ONCOLOGY Vol. 21 (pp. 402-403). Retrieved from http://gateway.webofknowledge.com/

    IPILIMUMAB IMPROVES SURVIVAL IN PREVIOUSLY TREATED, ADVANCED MELANOMA PATIENTS WITH POOR PROGNOSTIC FACTORS: SUBGROUP ANALYSES FROM A PHASE III TRIAL (Conference Paper)

    Lebbe, C., McDermott, D. F., Robert, C., Lorigan, P., Ottensmeier, C. H., Wolchok, J., . . . Weber, J. S. (2010). IPILIMUMAB IMPROVES SURVIVAL IN PREVIOUSLY TREATED, ADVANCED MELANOMA PATIENTS WITH POOR PROGNOSTIC FACTORS: SUBGROUP ANALYSES FROM A PHASE III TRIAL. In ANNALS OF ONCOLOGY Vol. 21 (pp. 401). Retrieved from http://gateway.webofknowledge.com/

    IPILIMUMAB PRODUCES DURABLE OBJECTIVE RESPONSES IN PATIENTS WITH PREVIOUSLY TREATED, ADVANCED MELANOMA: RESULTS FROM A PHASE III TRIAL (Conference Paper)

    Ottensmeier, C., Weber, R., Haanen, J. B., Robert, C., Schadendorf, D., Lutzky, J., . . . O'day, S. (2010). IPILIMUMAB PRODUCES DURABLE OBJECTIVE RESPONSES IN PATIENTS WITH PREVIOUSLY TREATED, ADVANCED MELANOMA: RESULTS FROM A PHASE III TRIAL. In ANNALS OF ONCOLOGY Vol. 21 (pp. 401-402). Retrieved from http://gateway.webofknowledge.com/

    RE-INDUCTION WITH IPILIMUMAB, GP100 PEPTIDE VACCINE, OR A COMBINATION OF BOTH IN A PHASE III STUDY OF PREVIOUSLY-TREATED PATIENTS WITH ADVANCED MELANOMA: UPDATE OF CLINICAL CHARACTERISTICS OF PATIENTS (Conference Paper)

    Robert, C., Hodi, F. S., O'Day, S. J., Peschel, C., Ottensmeier, C. H., Trefzer, U., . . . Schadendorf, D. (2010). RE-INDUCTION WITH IPILIMUMAB, GP100 PEPTIDE VACCINE, OR A COMBINATION OF BOTH IN A PHASE III STUDY OF PREVIOUSLY-TREATED PATIENTS WITH ADVANCED MELANOMA: UPDATE OF CLINICAL CHARACTERISTICS OF PATIENTS. In ANNALS OF ONCOLOGY Vol. 21 (pp. 403-404). Retrieved from http://gateway.webofknowledge.com/

    Response definition criteria for ELISPOT assays revisited (Journal article)

    Moodie, Z., Price, L., Gouttefangeas, C., Mander, A., Janetzki, S., Loewer, M., . . . Britten, C. M. (2010). Response definition criteria for ELISPOT assays revisited. CANCER IMMUNOLOGY IMMUNOTHERAPY, 59(10), 1489-1501. doi:10.1007/s00262-010-0875-4

    DOI: 10.1007/s00262-010-0875-4

    Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (Journal article)

    Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., . . . Urba, W. J. (2010). Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. NEW ENGLAND JOURNAL OF MEDICINE, 363(8), 711-723. doi:10.1056/NEJMoa1003466

    DOI: 10.1056/NEJMoa1003466

    Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine (Journal article)

    Dangoor, A., Lorigan, P., Keilholz, U., Schadendorf, D., Harris, A., Ottensmeier, C., . . . Hawkins, R. (2010). Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. CANCER IMMUNOLOGY IMMUNOTHERAPY, 59(6), 863-873. doi:10.1007/s00262-009-0811-7

    DOI: 10.1007/s00262-009-0811-7

    A Cancer Research UK phase I study evaluating safety, tolerability, and biological effects of chimeric anti-CD40 monoclonal antibody (Mab), Chi Lob 7/4 (Conference Paper)

    Johnson, P. W., Steven, N. M., Chowdhury, F., Dobbyn, J., Hall, E., Ashton-Key, M., . . . Glennie, M. (2010). A Cancer Research UK phase I study evaluating safety, tolerability, and biological effects of chimeric anti-CD40 monoclonal antibody (Mab), Chi Lob 7/4. In JOURNAL OF CLINICAL ONCOLOGY Vol. 28. doi:10.1200/jco.2010.28.15_suppl.2507

    DOI: 10.1200/jco.2010.28.15_suppl.2507

    Clinical and immunological responses to a DNA fusion vaccine in patients with carcinoembryonic antigen-expressing tumors: A Cancer Research UK phase I/II study. (Conference Paper)

    Ottensmeier, C. H., Mander, A., McCann, K., Low, L., Hall, E., Bateman, A., . . . O'Callaghan, A. (2010). Clinical and immunological responses to a DNA fusion vaccine in patients with carcinoembryonic antigen-expressing tumors: A Cancer Research UK phase I/II study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 28. doi:10.1200/jco.2010.28.15_suppl.2579

    DOI: 10.1200/jco.2010.28.15_suppl.2579

    DNA vaccines against cancer come of age (Journal article)

    Stevenson, F. K., Ottensmeier, C. H., & Rice, J. (2010). DNA vaccines against cancer come of age. CURRENT OPINION IN IMMUNOLOGY, 22(2), 264-270. doi:10.1016/j.coi.2010.01.019

    DOI: 10.1016/j.coi.2010.01.019

    Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program (Journal article)

    Mander, A., Gouttefangeas, C., Ottensmeier, C., Welters, M. J. P., Low, L., van der Burg, S. H., & Britten, C. M. (2010). Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program. CANCER IMMUNOLOGY IMMUNOTHERAPY, 59(4), 619-627. doi:10.1007/s00262-009-0814-4

    DOI: 10.1007/s00262-009-0814-4

    2009

    First case report of Muir-Torre syndrome associated with non-small cell lung cancer (Journal article)

    Nolan, L., Eccles, D., Cross, E., Crawford, G., Beck, N., Bateman, A., & Ottensmeier, C. (2009). First case report of Muir-Torre syndrome associated with non-small cell lung cancer. FAMILIAL CANCER, 8(4), 359-362. doi:10.1007/s10689-009-9247-7

    DOI: 10.1007/s10689-009-9247-7

    DNA Vaccination with Electroporation Induces Increased Antibody Responses in Patients with Prostate Cancer (Journal article)

    Low, L., Mander, A., McCann, K., Dearnaley, D., Tjelle, T., Mathiesen, I., . . . Ottensmeier, C. H. (2009). DNA Vaccination with Electroporation Induces Increased Antibody Responses in Patients with Prostate Cancer. HUMAN GENE THERAPY, 20(11), 1269-1278. doi:10.1089/hum.2009.067

    DOI: 10.1089/hum.2009.067

    Randomized Double-Blind Placebo-Controlled Trial of Thalidomide in Combination With Gemcitabine and Carboplatin in Advanced Non-Small-Cell Lung Cancer (Journal article)

    Lee, S. M., Rudd, R., Woll, P. J., Ottensmeier, C., Gilligan, D., Price, A., . . . Hackshaw, A. (2009). Randomized Double-Blind Placebo-Controlled Trial of Thalidomide in Combination With Gemcitabine and Carboplatin in Advanced Non-Small-Cell Lung Cancer. JOURNAL OF CLINICAL ONCOLOGY, 27(31), 5248-5254. doi:10.1200/JCO.2009.21.9733

    DOI: 10.1200/JCO.2009.21.9733

    Primary central nervous system lymphoma: tumor-related clones exist in the blood and bone marrow with evidence for separate development (Journal article)

    McCann, K. J., Ashton-Key, M., Smith, K., Stevenson, F. K., & Ottensmeier, C. H. (2009). Primary central nervous system lymphoma: tumor-related clones exist in the blood and bone marrow with evidence for separate development. BLOOD, 113(19), 4677-4680. doi:10.1182/blood-2008-09-179366

    DOI: 10.1182/blood-2008-09-179366

    Fit for purpose? A case study: validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines (Journal article)

    Mander, A., Chowdhury, F., Low, L., & Ottensmeier, C. H. (2009). Fit for purpose? A case study: validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines. CANCER IMMUNOLOGY IMMUNOTHERAPY, 58(5), 789-800. doi:10.1007/s00262-008-0633-z

    DOI: 10.1007/s00262-008-0633-z

    The Synthesis and in vivo Evaluation of 2 ',2 '-Difluoro KRN7000 (Journal article)

    Leung, L., Tomassi, C., Van Beneden, K., Decruy, T., Trappeniers, M., Elewaut, D., . . . Linclau, B. (2009). The Synthesis and in vivo Evaluation of 2 ',2 '-Difluoro KRN7000. CHEMMEDCHEM, 4(3), 329-334. doi:10.1002/cmdc.200800348

    DOI: 10.1002/cmdc.200800348

    Defining Multiple Myeloma as a Target for DNA Fusion Gene Vaccines (Conference Paper)

    Sahota, S. S., Zojer, N., Babbage, G., Joseph-Pietras, D., Weston-Bell, N., Vanderkerken, K., . . . Ottensmeier, C. H. (2009). Defining Multiple Myeloma as a Target for DNA Fusion Gene Vaccines. In CLINICAL LYMPHOMA & MYELOMA Vol. 9 (pp. S23-S24). doi:10.1016/S1557-9190(11)70813-7

    DOI: 10.1016/S1557-9190(11)70813-7

    2008

    Temporal activation of interferon regulatory factor-7 amplifies the performance of DNA vaccines in tolerant mice (Conference Paper)

    Shah, V., Slebioda, T. R., James, S., Ottensmeier, C. H., & Thirdborough, S. M. (2008). Temporal activation of interferon regulatory factor-7 amplifies the performance of DNA vaccines in tolerant mice. In IMMUNOLOGY Vol. 125 (pp. 49). Retrieved from http://gateway.webofknowledge.com/

    The relationship between invariant NKT cell frequency and cytokine diversity (Conference Paper)

    Gao, Y., Ottensmeier, C. H., Elliott, T. J., & Williams, A. P. (2008). The relationship between invariant NKT cell frequency and cytokine diversity. In IMMUNOLOGY Vol. 125 (pp. 90). Retrieved from http://gateway.webofknowledge.com/

    Synthesis and In Vivo Evaluation of 4-Deoxy-4,4-difluoro-KRN7000 (Journal article)

    Leung, L., Tomassi, C., Van Beneden, K., Decruy, T., Elewaut, D., Elliott, T., . . . Linclau, B. (2008). Synthesis and In Vivo Evaluation of 4-Deoxy-4,4-difluoro-KRN7000. ORGANIC LETTERS, 10(20), 4433-4436. doi:10.1021/ol801663m

    DOI: 10.1021/ol801663m

    Survival from melanoma of the skin in England and Wales up to 2001 - Clinical commentary (Journal article)

    Ottensmeier, C. H., & Gore, M. (2008). Survival from melanoma of the skin in England and Wales up to 2001 - Clinical commentary. BRITISH JOURNAL OF CANCER, 99, S50-S52. doi:10.1038/sj.bjc.6604586

    DOI: 10.1038/sj.bjc.6604586

    Synthesis and in vitro evaluation of alpha-GalCer epimers (Journal article)

    Trappeniers, M., Goormans, S., Van Beneden, K., Decruy, T., Linclau, B., Al-Shamkhani, A., . . . Van Calenbergh, S. (2008). Synthesis and in vitro evaluation of alpha-GalCer epimers. CHEMMEDCHEM, 3(7), 1061-1070. doi:10.1002/cmdc.200800021

    DOI: 10.1002/cmdc.200800021

    Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial (Journal article)

    Eggermont, A. M. M., Suciu, S., Santinami, M., Testori, A., Kruit, W. H. J., Marsden, J., . . . Grp, E. O. R. T. C. M. (2008). Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. LANCET, 372(9633), 117-126. doi:10.1016/S0140-6736(08)61033-8

    DOI: 10.1016/S0140-6736(08)61033-8

    Two randomised phase III, double blind, placebo controlled trials of thalidomide in patients with advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) (Conference Paper)

    Lee, S., Rudd, R. M., Woll, P. J., Ottensmeier, C. H., James, L. E., Gower, N. H., . . . Hackshaw, A. (2008). Two randomised phase III, double blind, placebo controlled trials of thalidomide in patients with advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 26. Retrieved from http://gateway.webofknowledge.com/

    Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial (Journal article)

    Muers, M. F., Stephens, R. J., Fisher, P., Darlison, L., Higgs, C. M. B., Lowry, E., . . . Grp, M. T. M. (2008). Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. LANCET, 371(9625), 1685-1694. doi:10.1016/S0140-6736(08)60727-8

    DOI: 10.1016/S0140-6736(08)60727-8

    Sound implementation of human papillomavirus vaccination as a community-randomized trial (Journal article)

    Lehtinen, M., French, K. M., Dillner, J., Paavonen, J., & Garnett, G. (2008). Sound implementation of human papillomavirus vaccination as a community-randomized trial. Therapy, 5(3), 289-294. doi:10.2217/14750708.5.3.289

    DOI: 10.2217/14750708.5.3.289

    Remarkable selective glycosylation of the immunoglobulin variable region in follicular lymphoma (Journal article)

    McCann, K. J., Ottensmeier, C. H., Callard, A., Radcliffe, C. M., Harvey, D. J., Dwek, R. A., . . . Stevenson, F. K. (2008). Remarkable selective glycosylation of the immunoglobulin variable region in follicular lymphoma. MOLECULAR IMMUNOLOGY, 45(6), 1567-1572. doi:10.1016/j.molimm.2007.10.009

    DOI: 10.1016/j.molimm.2007.10.009

    The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8(+) T lymphocytes by structural and functional assays (Journal article)

    Britten, C. M., Gouttefangeas, C., Welters, M. J. P., Pawelec, G., Koch, S., Ottensmeier, C., . . . van der Burg, S. H. (2008). The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8(+) T lymphocytes by structural and functional assays. CANCER IMMUNOLOGY IMMUNOTHERAPY, 57(3), 289-302. doi:10.1007/s00262-007-0378-0

    DOI: 10.1007/s00262-007-0378-0

    DNA vaccines: precision tools for activating effective immunity against cancer (Journal article)

    Rice, J., Ottensmeier, C. H., & Stevenson, F. K. (2008). DNA vaccines: precision tools for activating effective immunity against cancer. NATURE REVIEWS CANCER, 8(2), 108-120. doi:10.1038/nrc2326

    DOI: 10.1038/nrc2326

    Taking electroporation-based delivery of DNA vaccination into humans: a generic clinical protocol. (Journal article)

    Tjelle, T. E., Rabussay, D., Ottensmeier, C., Mathiesen, I., & Kjeken, R. (2008). Taking electroporation-based delivery of DNA vaccination into humans: a generic clinical protocol.. Methods in molecular biology (Clifton, N.J.), 423, 497-507. doi:10.1007/978-1-59745-194-9_39

    DOI: 10.1007/978-1-59745-194-9_39

    2007

    Cancer Vaccines (Chapter)

    Stevenson, F. K., Genova, G. D., Ottensmeier, C., & Savelyeva, N. (2007). Cancer Vaccines. In Cancer Immunotherapy (pp. 183-204). Elsevier. doi:10.1016/b978-012372551-6/50075-4

    DOI: 10.1016/b978-012372551-6/50075-4

    A phase III randomised, double blind, placebo controlled trial of gemcitabine/carboplatin with or without thalidomide in advanced non-small cell lung cancer (NSCLC) (Conference Paper)

    Siow-Ming, L., Woll, P. J., Rudd, R. M., Gower, N. H., Ottensmeier, C. H., Ali, K., . . . Hackshaw, A. (2007). A phase III randomised, double blind, placebo controlled trial of gemcitabine/carboplatin with or without thalidomide in advanced non-small cell lung cancer (NSCLC). In JOURNAL OF THORACIC ONCOLOGY Vol. 2 (pp. S359). doi:10.1097/01.JTO.0000283190.70038.e9

    DOI: 10.1097/01.JTO.0000283190.70038.e9

    An open-label phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma (Conference Paper)

    Eisen, T., Marais, R., Affolter, A., Lorigan, P., Ottensmeier, C., Robert, C., . . . Gore, M. (2007). An open-label phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma. In JOURNAL OF CLINICAL ONCOLOGY Vol. 25. Retrieved from http://gateway.webofknowledge.com/

    DNA vaccines to suppress myeloma (Conference Paper)

    Stevenson, E. K., Campos-Perez, J., Sahota, S., & Ottensmeier, C. (2007). DNA vaccines to suppress myeloma. In HAEMATOLOGICA-THE HEMATOLOGY JOURNAL Vol. 92 (pp. 45-46). Retrieved from http://gateway.webofknowledge.com/

    The CIMT monitoring panel: enumeration of antigen-specific CD8(+) T lymphocytes by structural and functional assays (Conference Paper)

    Britten, C. M., Gouttefangeas, C., Schoenmaekers-Welters, M. J. P., Pawelec, G., Koch, S., Ottensmeier, C., . . . van der Burg, S. H. (2007). The CIMT monitoring panel: enumeration of antigen-specific CD8(+) T lymphocytes by structural and functional assays. In CANCER IMMUNOLOGY IMMUNOTHERAPY Vol. 56 (pp. 406-407). Retrieved from http://gateway.webofknowledge.com/

    2006

    Phase I/II trial of a PrimeBoost therapeutic vaccine in stage III/IV metastatic melanoma. (Conference Paper)

    Hawkins, R. E., Dangoor, A., Keilholz, U., Schadendorf, D., Harris, A., Ottensmeier, C., . . . Pearce, G. (2006). Phase I/II trial of a PrimeBoost therapeutic vaccine in stage III/IV metastatic melanoma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 24 (pp. 460S). Retrieved from http://gateway.webofknowledge.com/

    Vinflunine - an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study (Journal article)

    Bennouna, J., Breton, J. -L., Tourani, J. -M., Ottensmeier, C., O'Brien, M., Kosmidis, P., . . . Douillard, J. -Y. (2006). Vinflunine - an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. BRITISH JOURNAL OF CANCER, 94(10), 1383-1388. doi:10.1038/sj.bjc.6603106

    DOI: 10.1038/sj.bjc.6603106

    Immunoglobulin heavy chain locus events and expression of activation-induced cytidine deaminase in epithelial breast cancer cell lines (Journal article)

    Babbage, G., Ottensmeier, C. H., Blaydes, J., Stevenson, F. K., & Sahota, S. S. (2006). Immunoglobulin heavy chain locus events and expression of activation-induced cytidine deaminase in epithelial breast cancer cell lines. CANCER RESEARCH, 66(8), 3996-4000. doi:10.1158/0008-5472.CAN-05-3704

    DOI: 10.1158/0008-5472.CAN-05-3704

    The Immunophenotyping of primary diffuse large B-cell lymphomas of the central nervous system (Conference Paper)

    Hickling, M., McCann, K., Ottensmeier, C., & Ashton-Key, M. (2006). The Immunophenotyping of primary diffuse large B-cell lymphomas of the central nervous system. In JOURNAL OF PATHOLOGY Vol. 208 (pp. 22A). Retrieved from http://gateway.webofknowledge.com/

    Universal N-glycosylation sites introduced into the B-cell receptor of follicular lymphoma by somatic mutation: a second tumorigenic event? (Journal article)

    McCann, K. J., Johnson, P. W. M., Stevenson, F. K., & Ottensmeier, C. H. (2006). Universal N-glycosylation sites introduced into the B-cell receptor of follicular lymphoma by somatic mutation: a second tumorigenic event?. LEUKEMIA, 20(3), 530-534. doi:10.1038/sj.leu.2404095

    DOI: 10.1038/sj.leu.2404095

    2005

    Immunogenetic profiling of follicular lymphoma reveals universal N-glycosylation sites introduced into the B cell receptor by somatic mutation and suggests relevance to lymphoma pathogenesis. (Conference Paper)

    Ottensmeier, C. H., McCann, K. J., Johnson, P., & Stevenoson, F. K. (2005). Immunogenetic profiling of follicular lymphoma reveals universal N-glycosylation sites introduced into the B cell receptor by somatic mutation and suggests relevance to lymphoma pathogenesis.. In BLOOD Vol. 106 (pp. 180A). Retrieved from http://gateway.webofknowledge.com/

    A DNA fusion gene vaccine induces epitope-specific cytotoxic T cells able to kill human cells expressing pp65 of cytomegalovirus (Conference Paper)

    King, A. T., Thirdborough, S. M., Rice, J., Khan, N., Stevenson, F. K., & Ottensmeier, C. H. (2005). A DNA fusion gene vaccine induces epitope-specific cytotoxic T cells able to kill human cells expressing pp65 of cytomegalovirus. In BRITISH JOURNAL OF SURGERY Vol. 92 (pp. 1304-1305). Retrieved from http://gateway.webofknowledge.com/

    Evaluation of a novel heterologous PrimeBoost immunotherapy in stage III/IV metastatic melanoma patients. (Conference Paper)

    Hawkins, R. E., Keilholz, U., Dangoor, A., Harris, A., Ottensmeier, C., Schadendorf, D., . . . Pearce, G. (2005). Evaluation of a novel heterologous PrimeBoost immunotherapy in stage III/IV metastatic melanoma patients.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 23 (pp. 183S). Retrieved from http://gateway.webofknowledge.com/

    Determining mutational status of immunoglobulin v genes in chronic lymphocytic leukemia: a useful prognostic indicator. (Journal article)

    Sahota, S. S., Babbage, G., Zojer, N., Ottensmeier, C. H., & Stevenson, F. K. (2005). Determining mutational status of immunoglobulin v genes in chronic lymphocytic leukemia: a useful prognostic indicator.. Methods in molecular medicine, 115, 129-144. doi:10.1385/1-59259-936-2:129

    DOI: 10.1385/1-59259-936-2:129

    Idiotype gene rescue in follicular lymphoma. (Journal article)

    McCann, K., Sahota, S. S., Stevenson, F. K., & Ottensmeier, C. H. (2005). Idiotype gene rescue in follicular lymphoma.. Methods in molecular medicine, 115, 145-171. doi:10.1385/1-59259-936-2:145

    DOI: 10.1385/1-59259-936-2:145

    2004

    Dose seeking evaluation of a novel heterologous primeboost immunotherapy in stage III and IV metastatic melanoma patients (Conference Paper)

    Malinoski, F., Hawkins, R., Ottensmeier, C., Smyth, J., Harris, A., Schadendorf, D., . . . Schneider, J. (2004). Dose seeking evaluation of a novel heterologous primeboost immunotherapy in stage III and IV metastatic melanoma patients. In JOURNAL OF IMMUNOTHERAPY Vol. 27 (pp. S27). doi:10.1097/00002371-200411000-00099

    DOI: 10.1097/00002371-200411000-00099

    DNA vaccines to attack cancer (Journal article)

    Stevenson, F. K., Ottensmeier, C. H., Johnson, P., Zhu, D. L., Buchan, S. L., McCann, K. J., . . . Rice, J. (2004). DNA vaccines to attack cancer. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 101, 14646-14652. doi:10.1073/pnas.0404896101

    DOI: 10.1073/pnas.0404896101

    Phase II study of IV Vinflunine (VFL) as second line treatment of patients (pts) with advanced non-small-cell lung cancer (NSCLC) previously treated with a platinum based regimen. Final results. (Conference Paper)

    Bennouna, J., Tan, E. H., Obrien, M., Kosmidis, P., Breton, J. L., Ottensmeier, C., . . . Douillard, J. Y. (2004). Phase II study of IV Vinflunine (VFL) as second line treatment of patients (pts) with advanced non-small-cell lung cancer (NSCLC) previously treated with a platinum based regimen. Final results.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 22 (pp. 651S). Retrieved from http://gateway.webofknowledge.com/

    DNA fusion gene vaccines against cancer: from the laboratory to the clinic (Journal article)

    Stevenson, F. K., Rice, J., Ottensmeier, C. H., Thirdborough, S. M., & Zhu, D. L. (2004). DNA fusion gene vaccines against cancer: from the laboratory to the clinic. IMMUNOLOGICAL REVIEWS, 199(1), 156-180. doi:10.1111/j.0105-2896.2004.00145.x

    DOI: 10.1111/j.0105-2896.2004.00145.x

    2003

    Anti-idiotype vaccines (Journal article)

    McCarthy, H., Ottensmeier, C. H., Hamblin, T. J., & Stevenson, F. K. (2003). Anti-idiotype vaccines. BRITISH JOURNAL OF HAEMATOLOGY, 123(5), 770-781. doi:10.1046/j.1365-2141.2003.04698.x

    DOI: 10.1046/j.1365-2141.2003.04698.x

    Vaccine therapy in NHL: Future promises and current limitations (Conference Paper)

    Stevenson, F. K., King, A., & Ottensmeier, C. H. (2003). Vaccine therapy in NHL: Future promises and current limitations. In LEUKEMIA & LYMPHOMA Vol. 44 (pp. S85-S90). doi:10.1080/10428190310001623711

    DOI: 10.1080/10428190310001623711

    DNA vaccination in B cell malignancies and solid tumours (Conference Paper)

    Ottensmeier, C. (2003). DNA vaccination in B cell malignancies and solid tumours. In BRITISH JOURNAL OF CANCER Vol. 88 (pp. S2). Retrieved from http://gateway.webofknowledge.com/

    Incidence of potential glycosylation sites in immunoglobulin variable regions distinguishes between subsets of Burkitt's lymphoma and mucosa-associated lymphoid tissue lymphoma (Journal article)

    Zhu, D., Ottensmeier, C. H., Du, M. Q., McCarthy, H., & Stevenson, F. K. (2003). Incidence of potential glycosylation sites in immunoglobulin variable regions distinguishes between subsets of Burkitt's lymphoma and mucosa-associated lymphoid tissue lymphoma. BRITISH JOURNAL OF HAEMATOLOGY, 120(2), 217-222. doi:10.1046/j.1365-2141.2003.04064.x

    DOI: 10.1046/j.1365-2141.2003.04064.x

    Origins of the malignant clone in typical Waldenstrom's macroglobulinernia (Journal article)

    Sahota, S. S., Forconi, F., Ottensmeier, C. H., & Stevenson, F. K. (2003). Origins of the malignant clone in typical Waldenstrom's macroglobulinernia. SEMINARS IN ONCOLOGY, 30(2), 136-141. doi:10.1053/sonc.2003.50072

    DOI: 10.1053/sonc.2003.50072

    2002

    Glycosylation sites in the surface Ig of B-cell malignancies: A substitute for antigen in maintaining tumor survival in the germinal center? (Conference Paper)

    Stevenson, F. K., Zhu, D. L., Ottensmeier, C. H., Du, M. Q., & McCarthy, H. (2002). Glycosylation sites in the surface Ig of B-cell malignancies: A substitute for antigen in maintaining tumor survival in the germinal center?. In BLOOD Vol. 100 (pp. 157A). Retrieved from http://gateway.webofknowledge.com/

    Glycosylation of V region genes in follicular lymphoma as a result of the somatic hypermutation mechanism (Journal article)

    Belessi, C., Stamatopoulos, K., & Kosmas, C. (2002). Glycosylation of V region genes in follicular lymphoma as a result of the somatic hypermutation mechanism. BLOOD, 100(6), 2269-2270. doi:10.1182/blood-2002-05-1403

    DOI: 10.1182/blood-2002-05-1403

    High incidence of novel N-glycosylation sites in the immunoglobulin variable region genes of follicular lymphoma (Journal article)

    Zhu, D. L., McCarthy, H., Ottensmeier, C. H., Johnson, P., Hamblin, T. J., & Stevenson, F. K. (2002). High incidence of novel N-glycosylation sites in the immunoglobulin variable region genes of follicular lymphoma. BLOOD, 100(6), 2270-2271. Retrieved from http://gateway.webofknowledge.com/

    Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events (Journal article)

    Sahota, S. S., Forconi, F., Ottensmeier, C. H., Provan, D., Oscier, D. G., Hamblin, T. J., & Stevenson, F. K. (2002). Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. BLOOD, 100(4), 1505-1507. doi:10.1182/blood.V100.4.1505.h81602001505_1505_1507

    DOI: 10.1182/blood.V100.4.1505.h81602001505_1505_1507

    Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma (Journal article)

    Zhu, D. L., McCarthy, H., Ottensmeier, C. H., Johnson, P., Hamblin, T. J., & Stevenson, F. K. (2002). Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. BLOOD, 99(7), 2562-2568. doi:10.1182/blood.V99.7.2562

    DOI: 10.1182/blood.V99.7.2562

    DNA vaccination against cancer (Conference Paper)

    Stevenson, F. K., Ottensmeier, C. H., McCarthy, H., Di Genova, G., Snow, R., Zhu, D., . . . Rice, J. (2002). DNA vaccination against cancer. In INTERNATIONAL JOURNAL OF CANCER (pp. 16-17). Retrieved from http://gateway.webofknowledge.com/

    2001

    Typical Waldenstrom's macroglobulinemia and IgM-secreting MGUS are each derived from B-cells arrested following cessation of somatic mutation but prior to isotype switch events. (Conference Paper)

    Sahota, S. S., Forconi, F., Ottensmeier, C. H., Provan, D., Oscier, D. G., Hamblin, T. J., & Stevenson, F. K. (2001). Typical Waldenstrom's macroglobulinemia and IgM-secreting MGUS are each derived from B-cells arrested following cessation of somatic mutation but prior to isotype switch events.. In BLOOD Vol. 98 (pp. 154A). Retrieved from http://gateway.webofknowledge.com/

    A phase I and pharmacokinetic study of vinflunine given on days 1 and 8 every 3 weeks (Conference Paper)

    Johnson, P., Judson, I., Ottensmeier, C., O'Donnell, A., Pinel, M. C., Puozzo, C., & Fumoleau, P. (2001). A phase I and pharmacokinetic study of vinflunine given on days 1 and 8 every 3 weeks. In BRITISH JOURNAL OF CANCER Vol. 85 (pp. 94). Retrieved from http://gateway.webofknowledge.com/

    The assessment of immune capacity in patients with B cell malignancies (Conference Paper)

    McCarthy, H., Ottensmeier, C., Chilton, S., Duncombe, A., Johnson, P., Hamblin, T., & Stevenson, F. (2001). The assessment of immune capacity in patients with B cell malignancies. In BRITISH JOURNAL OF CANCER Vol. 85 (pp. 59). Retrieved from http://gateway.webofknowledge.com/

    The classification of lymphomas and leukemias (Conference Paper)

    Ottensmeier, C. (2001). The classification of lymphomas and leukemias. In CHEMICO-BIOLOGICAL INTERACTIONS Vol. 135 (pp. 653-664). doi:10.1016/S0009-2797(01)00201-0

    DOI: 10.1016/S0009-2797(01)00201-0

    The occurrence and significance of V gene mutations in B cell-derived human malignancy (Journal article)

    Stevenson, F. K., Sahota, S. S., Ottensmeier, C. H., Zhu, D. L., Forconi, F., & Hamblin, T. J. (2001). The occurrence and significance of V gene mutations in B cell-derived human malignancy. ADVANCES IN CANCER RESEARCH, VOL 83, 83, 81-116. doi:10.1016/S0065-230X(01)83004-9

    DOI: 10.1016/S0065-230X(01)83004-9

    2000

    Isotype switch variants reveal clonally related subpopulations in diffuse large B-cell lymphoma (Journal article)

    Ottensmeier, C. H., & Stevenson, F. K. (2000). Isotype switch variants reveal clonally related subpopulations in diffuse large B-cell lymphoma. BLOOD, 96(7), 2550-2556. Retrieved from http://gateway.webofknowledge.com/

    Isotype switch variants reveal clonally-related subpopulations in diffuse large B cell lymphomas: Insights into the biology of germinal centre lymphomas (Conference Paper)

    Ottensmeier, C. H., Wilkins, B. S., Sweetenham, J. W., & Stevenson, F. K. (2000). Isotype switch variants reveal clonally-related subpopulations in diffuse large B cell lymphomas: Insights into the biology of germinal centre lymphomas. In BRITISH JOURNAL OF CANCER Vol. 83 (pp. 83). Retrieved from http://gateway.webofknowledge.com/

    1999

    Immunocytochemical assessment of bone marrow aspirates for monitoring response to chemotherapy in small-cell lung cancer patients (Journal article)

    Pelosi, G., Pasini, F., Ottensmeier, C., Pavanel, F., Bresaola, E., Bonetti, A., . . . Cetto, G. L. (1999). Immunocytochemical assessment of bone marrow aspirates for monitoring response to chemotherapy in small-cell lung cancer patients. BRITISH JOURNAL OF CANCER, 81(7), 1213-1221. doi:10.1038/sj.bjc.6690831

    DOI: 10.1038/sj.bjc.6690831

    1998

    Analysis of V-H genes in follicular and diffuse lymphoma shows ongoing somatic mutation and multiple isotype transcripts in early disease with changes during disease progression (Journal article)

    Ottensmeier, C. H., Thompsett, A. R., Zhu, D. L., Wilkins, B. S., Sweetenham, J. W., & Stevenson, F. K. (1998). Analysis of V-H genes in follicular and diffuse lymphoma shows ongoing somatic mutation and multiple isotype transcripts in early disease with changes during disease progression. BLOOD, 91(11), 4292-4299. doi:10.1182/blood.V91.11.4292.411a02_4292_4299

    DOI: 10.1182/blood.V91.11.4292.411a02_4292_4299

    Insight into the origin and clonal history of B-cell tumors as revealed by analysis of immunoglobulin variable region genes (Journal article)

    Stevenson, F., Sahota, S., Zhu, D. L., Ottensmeier, C., Chapman, C., Oscier, D., & Hamblin, T. (1998). Insight into the origin and clonal history of B-cell tumors as revealed by analysis of immunoglobulin variable region genes. IMMUNOLOGICAL REVIEWS, 162, 247-259. doi:10.1111/j.1600-065X.1998.tb01446.x

    DOI: 10.1111/j.1600-065X.1998.tb01446.x

    1997

    Immunogenetic features of diffuse and follicular lymphoma vary with disease status and reveal multiple isotype expression. (Conference Paper)

    Ottensmeier, C. H., Wilkins, B. S., & Stevenson, F. K. (1997). Immunogenetic features of diffuse and follicular lymphoma vary with disease status and reveal multiple isotype expression.. In BLOOD Vol. 90 (pp. 3932). Retrieved from http://gateway.webofknowledge.com/

    1996

    Absence of constitutive EGF receptor activation in ovarian cancer cell lines (Journal article)

    Ottensmeier, C., Swanson, L., Strobel, T., Druker, B., Niloff, J., & Cannistra, S. A. (1996). Absence of constitutive EGF receptor activation in ovarian cancer cell lines. BRITISH JOURNAL OF CANCER, 74(3), 446-452. doi:10.1038/bjc.1996.379

    DOI: 10.1038/bjc.1996.379

    Histological transformation of indolent (follicular) lymphoma (Journal article)

    Ottensmeier, C., & Mead, G. (1996). Histological transformation of indolent (follicular) lymphoma. ANNALS OF ONCOLOGY, 7(8), 849-853. Retrieved from http://gateway.webofknowledge.com/

    1995

    FUNCTIONAL-HETEROGENEITY OF CD44 MOLECULES IN OVARIAN-CANCER CELL-LINES (Journal article)

    CANNISTRA, S. A., DEFRANZO, B., NILOFF, J., & OTTENSMEIER, C. (1995). FUNCTIONAL-HETEROGENEITY OF CD44 MOLECULES IN OVARIAN-CANCER CELL-LINES. CLINICAL CANCER RESEARCH, 1(3), 333-342. Retrieved from http://gateway.webofknowledge.com/

    CD44 VARIANT EXPRESSION IS A COMMON FEATURE OF EPITHELIAL OVARIAN-CANCER - LACK OF ASSOCIATION WITH STANDARD PROGNOSTIC FACTORS (Journal article)

    CANNISTRA, S. A., ABUJAWDEH, G., NILOFF, J., STROBEL, T., SWANSON, L., ANDERSEN, J., & OTTENSMEIER, C. (1995). CD44 VARIANT EXPRESSION IS A COMMON FEATURE OF EPITHELIAL OVARIAN-CANCER - LACK OF ASSOCIATION WITH STANDARD PROGNOSTIC FACTORS. JOURNAL OF CLINICAL ONCOLOGY, 13(8), 1912-1921. doi:10.1200/JCO.1995.13.8.1912

    DOI: 10.1200/JCO.1995.13.8.1912

    EXPRESSION AND FUNCTION OF BETA-1 AND ALPHA-V-BETA-3 INTEGRINS IN OVARIAN-CANCER (Journal article)

    CANNISTRA, S. A., OTTENSMEIER, C., NILOFF, J., ORTA, B., & DICARLO, J. (1995). EXPRESSION AND FUNCTION OF BETA-1 AND ALPHA-V-BETA-3 INTEGRINS IN OVARIAN-CANCER. GYNECOLOGIC ONCOLOGY, 58(2), 216-225. doi:10.1006/gyno.1995.1214

    DOI: 10.1006/gyno.1995.1214

    1994

    VASCULAR CELL-ADHESION MOLECULE-1 EXPRESSED BY PERITONEAL MESOTHELIUM PARTLY MEDIATES THE BINDING OF ACTIVATED HUMAN T-LYMPHOCYTES (Journal article)

    CANNISTRA, S. A., OTTENSMEIER, C., TIDY, J., & DEFRANZO, B. (1994). VASCULAR CELL-ADHESION MOLECULE-1 EXPRESSED BY PERITONEAL MESOTHELIUM PARTLY MEDIATES THE BINDING OF ACTIVATED HUMAN T-LYMPHOCYTES. EXPERIMENTAL HEMATOLOGY, 22(10), 996-1002. Retrieved from http://gateway.webofknowledge.com/

    1993

    BINDING OF OVARIAN-CANCER CELLS TO PERITONEAL MESOTHELIUM IN-VITRO IS PARTLY MEDIATED BY CD44H (Journal article)

    CANNISTRA, S. A., KANSAS, G. S., NILOFF, J., DEFRANZO, B., KIM, Y., & OTTENSMEIER, C. (1993). BINDING OF OVARIAN-CANCER CELLS TO PERITONEAL MESOTHELIUM IN-VITRO IS PARTLY MEDIATED BY CD44H. CANCER RESEARCH, 53(16), 3830-3838. Retrieved from http://gateway.webofknowledge.com/

    1992

    INTERLEUKIN-2 FOLLOWED BY FLUOROURACIL AND FOLINIC ACID IN REFRACTORY COLORECTAL-CANCER - RESULTS OF A CLINICAL PHASE-II STUDY (Journal article)

    HIDDEMANN, W., RUELFS, C., OTTENSMEIER, C., RUCKLE, H., MUSCH, E., KOCH, O., & VANDELOO, J. (1992). INTERLEUKIN-2 FOLLOWED BY FLUOROURACIL AND FOLINIC ACID IN REFRACTORY COLORECTAL-CANCER - RESULTS OF A CLINICAL PHASE-II STUDY. SEMINARS IN ONCOLOGY, 19(2), 225-227. Retrieved from http://gateway.webofknowledge.com/

    1991

    TREATMENT OF ADVANCED CHRONIC LYMPHOCYTIC-LEUKEMIA BY FLUDARABINE - RESULTS OF A CLINICAL PHASE-II STUDY (Journal article)

    HIDDEMANN, W., ROTTMANN, R., WORMANN, B., THIEL, A., ESSINK, M., OTTENSMEIER, C., . . . VANDELOO, J. (1991). TREATMENT OF ADVANCED CHRONIC LYMPHOCYTIC-LEUKEMIA BY FLUDARABINE - RESULTS OF A CLINICAL PHASE-II STUDY. ANNALS OF HEMATOLOGY, 63(1), 1-4. doi:10.1007/BF01714952

    DOI: 10.1007/BF01714952

    1985

    [Incidence and significance of DNA aneuploidies in breast tumors] (Journal article)

    Hiddemann, W., Müller, K. M., von Bassewitz, D. B., Ottensmeier, C., Meyer Kramer, J., & Büchner, T. (1985). [Incidence and significance of DNA aneuploidies in breast tumors]. Verhandlungen der Deutschen Gesellschaft fur Pathologie, 69, 545-548.